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1 - INTRODUCTION 
Prion diseases are perhaps the most mysterious and peculiar diseases in 
nature. These diseases do not rely on the general dogmas of modern biology, 
seen in other infectious diseases caused by conventional pathogens, such as 
viruses and bacteria. On the contrary, their infectious agent is an 
unconventional proteinaceous pathogen, termed prion, that lacks functional 
nucleic acids. Prion diseases are also known as Transmissible Spongiform 
Encephalopathies (TSEs), because the diseases are transmissible from one 
host to another and manifest a spongiform appearance as result of the 
destruction of brain tissue during a long incubation period (Prusiner, 1982; 
Prusiner, 1998). Prion diseases include Creutzfeldt-Jakob disease in humans, 
bovine spongiform encephalopathy (BSE, “mad cow disease”) in cattle, 
scrapie in sheep and chronic wasting disease in deer and elks. As 
demonstrated in the BSE outbreak and its transmission to humans, the onset 
of diseases is not limited to a certain species but can be transmissible from 
one host species to another. Such a striking nature of prion has generated 
huge concerns in public health and attracted serious attention in the scientific 
communities.  
To date, the potential transmission of prions to human has not been alleviated 
and TSEs still have no reliable preclinical screening tests and effective 
treatments. To comprehend the threat of prion diseases and to develop 
diagnostics and therapeutics, it is important to understand how prions 
emerge, replicate and transmit (Ryou et al., 2007) 
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2- TSEs IN HISTORY 
In the political and economic turmoil of the 18th century Europe, England 
gradually established itself as the dominant trading power. In that setting, 
TSEs appear for the first time in official documents. In 1755 in fact, a 
discussion took place in the British parliament about the economic effects of a 
fatal and spreading disease in sheep and about the need for government to 
do something about it, because it was having serious repercussions on the 
economy of the Country, at that time leader in the wool trade (Journal of the 
House of Commons, 1755; Brown et al., 1998) 
That pathology was the scrapie (name derived from the English verb “to 
scrape”), whose clinical symptoms were described in a German newspaper in 
1759: “Some sheep also suffer from scrapie, which can be identified by the 
fact that affected animals lie down, bite at their feet and legs, rub their backs 
against posts, fail to thrive, stop feeding and finally become lame. They drag 
themselves along, gradually become emaciated and die”. The same article 
reported that scrapie was a contagious diseases in sheep but not in humans 
and suggested to dispose of them quickly and slaughter them away from the 
manorial lands (Brown et al., 1998). 
Although in 1772 scrapie was considered to be a widespread disease in 
England for forty years, no evidence had ever been found (Schneider et al., 
2008). 
Where and how it appeared for the first time it is still a mystery, even though 
commonly it is believed that the export of Merino sheep from Spain has 
played a key role in its spread (Brown et al., 1998). 
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Around the middle of the 19th century, veterinarians in England, France and 
German initiated the scientific study of scrapie, including systematic 
neuropathological examinations, and made efforts to identify an infectious 
pathogen. In particular, Besnoit and his colleagues in the Toulouse school of 
veterinary medicine recognised neuronal vacuolation as a characteristic 
feature (Besnoit et al., 1898; Brown et al., 1998). In 1936 other two French 
doctors, Cuillé and Chelle, pointed out the intraspecies transmissibility of 
scrapie, succeeding in transmitting it to two healthy sheep by intraocular 
inoculation of brain or spinal cord tissue from an affected animal. In 
subsequent experiments, they also transmitted scrapie by using intracerebral, 
epidural and subcutaneous routes of infection (Cuillé et al., 1936; Brown et 
al., 1998).  
Tragically in the same period in England the transmissible nature of the 
scrapie agent was  confirmed beyond any doubt, by an outbreak of scrapie in 
several hundred sheep that had been immunised against louping ill with a 
vaccine prepared from tissue from the brain, spinal cord and spleen of sheep 
that were belatedly discovered to have been exposed to natural scrapie 
infection (Gordon, 1946; Brown et al., 1998). 
Throughout the 1940s and 1950s the accelerating pace of veterinary research 
yielded many new discoveries about the behaviour of the causative agent: its 
distributions through the whole body after experimental and natural infection, 
its physical association with cell membranes, its susceptibility to host genetic 
factors and its extraordinary resistance to standard methods of inactivation 
(Brown et al., 1998). In 1961 Chandler managed to adapt it to laboratory mice, 
eliciting a collective sigh of relief for experimentalists, who had until then 
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obliged to work exclusively with sheep and goats, the only animals naturally 
susceptible (Chandler, 1961; Brown et al., 1998). 
The first description of a human TSE was made in 1920 by two German 
neuropathologists, who gave their names to that new pathology: the 
Creutzfeldt-Jakob Disease (CJD). It was characterised by a progressive and 
fatal neurodegeneration that, unlike scrapie, occurred sporadically (with a 
frequency of about one case per million individuals per year worldwide) with a 
genetic predisposition (Norrby, 2011). 
Sixteen years later a familiar form of human TSE was reported by Gerstman 
and his colleagues: the Gerstman-Straussler-Scheinker (GSS) Syndrome  
(Gerstman et al., 1936; Collins et al., 2001)  
In the 1947 in Wisconsin and Minnesota (USA) was recognised for the first 
time the Transmissible Mink Encephalopathy (TME) (Marsh et al., 1991; 
Marsh et al., 1992; Sigurdson et al., 2003). It is a rare fatal neurological 
disease, which appears sporadically in farmed mink and, after an incubation 
period estimated at 7-12 months, induces behavioural changes including 
aggressiveness, hyperesthesia and progressive ataxia, drowsiness, 
weakness, until the inevitable death. TME has been largely confined to USA, 
although incidents have also occurred in Canada, Finland, Germany and 
Russia (Marsh et al. 1993; Sigurdson et al., 2003) 
Its origins have not yet been established, although it is common to think that 
its onset is linked to the use of food contaminated with the causative agent of 
scrapie.  
Controversly, the last reported outbreak of TME, appeared in Stetsonville, 
Wisconsin, occurred in minks that were never been fed with meat of sheep 
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but that had downer cattle as a primary source of food, leading to 
speculations on a potentially unrecognised BSE-like (see below) disease of 
American cattle, never confirmed (Marsh et al., 1993; Sigurdson et al., 2003). 
In 1959 Hadlow, an American veterinarian, had an important insight, which led 
to have a broader look and aware on many diseases until then considered 
individually. He was the first to suggest a link between animal and human 
TSEs, speculating that scrapie could be an animal pathology similar to kuru 
(Hadlow, 1959), fatal disease spread among the Fore tribe of Aborigines, in 
Papua New Guinea, described by Gajdusek and Zigas in 1957. 
Kuru mainly affected women and children, causing motor dyskinesias, ataxia, 
facial spasms, swallowing difficulty, tremors and muscle jerks (myoclonus) 
(Brown et al., 1998).  
The histological analysis of samples of brain tissue taken post-mortem from 
people affected by kuru (Klatso et al., 1959) allowed to observe significant 
similarities with the  degenerative lesions seen in patients who died from CJD 
and, as noted by Hadlow (Hadlow, 1959), in sheep with scrapie. 
The ritual cannibalism practiced by the Fore people was found to be the route 
of transmission of kuru. In fact, they used to prepare the bodies of the 
deceased relatives for the funeral meals and the central nervous system, 
containing the largest concentration of the infectious agent, was consumed 
mainly by women and children. 
Since 1960, the year of the abolition of cannibalism, no new born has 
contracted kuru, and the latest victim died in the 21st century, after an 
incubation period longer than 40 years (Collinge et al., 2006; Norrby, 2011). 
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Gajdusek himself managed to prove the infectivity of kuru. He and his 
collaborators indeed were successful in transmitting first kuru (Gajdusek et al., 
1966) and then CJD (Gibbs et al., 1968) by intracerebral inoculation to 
chimpanzees. For his important scientific discoveries, Gajdusek obtained the 
Nobel Prize in Medicine in 1976. 
In Colorado (USA) in 1967 a TSE able to affect not only farmed animals but 
also free-ranging wild-life ones was described: the Chronic Wasting Disease 
(CWD). It is a disease of Rocky Mountain Elk, Mule deer, Black-Tailed Deer, 
White-Tailed Deer and Moose. Because Red Deer are genetically very similar 
to Rocky Mountain Elk, it is likely that they are also susceptible to CWD. Early 
signs in clinically affected deer and elk are extremely subtle and include 
weight loss, behavioural alterations, a lowered head and drooping ears. As 
clinical disease progresses, more noticeable signs like flaccid hypotonic facial 
muscles, excessive salivation, regurgitation of ruminal fluid, ruminal atony and 
polyuria and polydipsia arise. Individuals may develop aspiration pneumonia 
in late stage disease. Itching and loss of fleece, the characteristic signs of the 
end stage of scrapie, are not observed (Williams et al., 1980; Sigurdson et al., 
2003; Williams, 2005). Until now, CWD has been reported only in North 
America, where its prevalence and geographical distribution appears to be 
increasing. Cases of CWD have also been reported in the Republic of Korea, 
although these are probably linked to elk exported from Canada (Defra). The 
origin of CWD is unknown and the disease transmits in the absence of 
contaminated feed. The precise mechanism of transmission is unclear. It is 
possible that the infectious agent is shed in the saliva, faeces or urine or as a 
result of decomposition of infected carcases and transferred to other cervids 
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grazing the contaminated areas. It is also possible that some maternal 
transmission occurs (Sigurdson et al., 2003; Defra). Experimental studies 
seem to exclude the possibility for the infective agent to jump the species 
barrier and affect humans or cattle (Sigurdson et al., 2003). 
TSEs have been detected also in exotic ruminants in United Kingdom (UK) 
zoos since 1986. These include antelopes (Eland, Gemsbok, Arabian and 
Scimitar oryx, Nyala and Kudu), Ankole cattle and Bison. With hindsight the 
1986 case in Nyala was diagnosed before the first case of BSE (see below) 
was identified. The TSE cases in exotic ruminants had a younger onset age 
and a shorter clinical duration compared to that in cattle with BSE. All the 
cases appear to be linked to the BSE epidemic via the consumption of feed 
contaminated with the BSE agent. The epidemic has declined as a result of 
tight controls on feeding mammalian meat and bone meal to susceptible 
animals, particularly from August 1996 (Sigurdson et al., 2003;  Defra).  
The same fate befell to the Feline Spongiform Encephalopathy, described in 
1990 in the United Kingdom. It has been reported in cats and other felines in 
captivity (Cheetah, Lion, Asian leopard cat, Ocelot, Puma and Tiger) and is 
believed to have a common origin with the TSEs in the exotic ruminants. The 
disease is characterised by progressive nervous signs, including ataxia, 
hyper-reactivity and behavioural changes and is fatal (Sigurdson et al. 2003; 
Defra). 
In October 1986, the first case of the Fatal Familial Insomnia (FFI) was 
recorded in Italy. The patient affected showed progressive insomnia, fever, 
tremors and other motor disorders, until coma and death nine months after 
the onset of symptoms. As the name suggests, the FFI has a familial 
  
 
8
occurrence, linked to a dominant autosomal genetic mutation (Lugaresi et al., 
1986). 
The first confirmed cases of BSE were recognised in Great Britain in 
November 1986, following referral of the brain of two cows with unusual 
progressive neurological signs from two veterinary investigation centres in 
Southern England to the Pathology Department of the Central Veterinary 
Laboratory in Weybridge (now Animal Health Veterinary Laboratory Agency – 
AHVLA). The disease was recognised as a spongiform encephalopathy 
because of the neuropathological similarity to that seen in the scrapie-affected 
sheep (Wells et al., 1987; Smith et al., 2003).  
This new disease of cattle was characterised by a slow but progressive and 
always fatal clinical course, which resulted the affected animals in mental, 
sensory, postural and motor disorders, as well as weight loss and lower 
efficiency in dairy cows (Cranwell et al. 1988; Wilesmith et al., 1988). The 
clinical signs were very variable, however, often subtle and certainly not 
pathognomonic (Braun et al. 1997; Caveau et al. 2004; Konold et al., 2006)  
Since 1986 many other cases of BSE were identified, especially in Great 
Britain, and, after  the introduction in January 2001 in the European Union of 
the mandatory active surveillance (January 1999 in Switzerland and spring 
2000 in France), BSE was found also in many other countries, where the 
mere passive surveillance had not been enough (Ducrot et al., 2008) (Figure 
1 and Table 1). 
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Figure 1. Number of BSE cases in the European Union between 1989 and 2005. Source 
European Commission, 2002 to 2006. Reports on the monitoring and testing of ruminants for 
the presence of transmissible spongiform encephalopathy (TSE) in the EU (Ducrot et al., 
2008). 
 
 
Table 1. Sequence of first report of BSE in native-born cattle (Smith et al., 2003) 
1986 UK 
1989 Ireland 
1990 Portugal 
1991 Switzerland 
1997 Belgium, Luxembourg, The Netherlands 
1998 Lichtenstein 
2000 Denmark, Germany Spain 
2001 Austria, Czech Republic, Finland, Greece, Italy, Japan, Slovakia, Slovenia 
2002 Israel, Poland 
2003 Canada 
 
There are retrospective evidences of the occurrence of the BSE clinical 
disease in April 1985 (Wilesmith et al., 1988) but it is likely that the first cases 
may have occurred in the early 1980s or even in 1970s (Horn et al., 2001; 
Smith et al., 2003).  
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The origin of BSE still remains unclear. The two main reliable theories 
suggest that it may be a cattle-adapted form of scrapie that crossed the 
species barrier from sheep to cattle (the scrapie hypothesis) or a sporadic 
cattle disease that first arose as a spontaneous disease in an individual cow 
(the sporadic bovine mutation hypothesis) (Wilesmith et al., 1988, Baylis et 
al., 2002, Smith et al., 2003). Even if research has not been able to solve this 
question, epidemiological studies managed to identify the transmission route 
of infection, allowing to take adequate measure to prevent it. These studies 
revealed that the use of meat-and-bone-meal (MBM) as a high protein 
supplement feed incorporated into concentrated rations was a linking feature 
on the farms from which cases had been reported. In the 1970s and 1980s 
the source materials for these end-products was from all species of farm 
animals, including fallen stock (animals dead on farm), abattoir and butcher's 
waste and condemned materials. The staring materials were cooked by 
various methods to evaporate water to steam and the tallow (fat) was 
separated by centrifugation or pressing, leaving a solid material, called 
greaves, from which MBM was derived by grinding. It was hypothesised that 
once the causative agent of BSE had been introduced into the rendering 
process it would be recycled to infect other cattle through MBM. 
MBM had been used in animal feed for decades and the rendering processes 
in use at that time were not probably completely effective at inactivating either 
the BSE agent or a range of scrapie agent, but in the late 1970s and early 
1980s in the European Union (1981 in the United Kingdom) the process used 
to extract tallow by rendering industry changed, presumably increasing the 
titre of TSE agents in MBM and consequently increasing the exposure of 
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cattle. It is likely that epidemic started in the UK because the ratio of sheep to 
cattle tissues going into rendering was higher there and because in the 1970s 
was the first country to start feeding MBM to young calves, particularly 
susceptible to infection with the BSE agent (Wilesmith et al., 1988; Wilesmith 
et al., 1991; Wilesmith et al., 1992). 
In the summer of 1988, two years after the identification of the first cases of 
BSE, Great Britain decreed the prohibition of use of meat from cattle and 
small ruminants to feed ruminants, the only animals considered susceptible. 
The effects of the ban were not immediate, probably due to the long 
incubation period of BSE (on average 5 years), but since 1993 the incidence 
of BSE in British cattle began to decline (Heim et al., 2000; Ducrot et al., 
2008). The feed ban had a major impact on the epidemic, but it was not as 
effective as had been hoped and cases of disease continued to occur in 
animals born after the feed control measures had been introduced. 
Epidemiological studies on these “born after the ban” (BAB) cases revealed 
that the greatest incidence was in eastern England, corresponding to the area 
with the greatest prevalence of pig farms. Further investigations led to the 
hypothesis that BAB cases of BSE might be attributable to accidental cross-
contamination of ruminant diets with MBM intended for pigs and poultry 
(Hoinville et al., 1995; Smith et al., 2003). The discovery that less than 1 g of 
infected cow brain could experimentally transmit BSE to further cows by the 
oral route lent weight to this hypothesis, as only a relatively small amount of 
such contamination would be required to induce disease (Smith et al., 2003; 
Wells et al., 2007; Ducrot et al. 2008). 
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Even the ban, introduced in 1990, on the use of specific bovine tissues 
(specified risk material - SRM) containing the most infectious material from 
cattle carcasses (spinal cord, tonsils, thymus, spleen and intestine) in the 
MBM for monogastric has not been found to completely remove the feed-born 
risk of exposure. The lack of complete effectiveness of the SRM ban is likely 
to be due to the difficulties of complete removal of some tissues and the 
possibility of residual risk in production plants from earlier periods (Smith et al. 
2003; Ducrot et al., 2008). 
The European Union (EU), which took longer to recognise its real involvement 
in the problem, banned the use of mammalian MBM for ruminants only in 
1994 (Ducrot et al., 2008). 
In 1996 the first article on the zoonotic aspect of BSE was published (Will et 
al., 1996) and consequently a total ban was placed on feeding mammalian 
protein to any farmed animals. The feed ban that was introduced in the UK in 
1996 was essentially the same as the feed ban that was introduced across 
the EU on January 1st 2001, five years later (Smith et al., 2003; Ducrot et al., 
2008). 
Even though until then it was considered that the same species barrier had 
preserved humans from scrapie would be effective also against BSE, clinically 
suspect or confirmed cases of BSE were banned from the human food chain 
in the UK in 1988 and in the EU in 1990 (Smith et al., 2003). In 1989 in the UK 
a specified bovine offal (SBO) ban was instituted. This prohibited bovine 
brain, spinal cord, tonsil thymus spleen and intestines from entering the 
human food chain (Smith et al., 2003; Norrby, 2011).  
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These measures were not enough to prevent the occurrence in 1995 of the 
first case of CJD putatively derived from the dietary exposure to the causative 
agent of BSE (Will et al., 1996). The histopathological pattern and the agent 
strain found in the affected man appeared to be consistent with the BSE ones 
(Bruce et al., 1997; Hill et al., 1997). This new form of CJD was referred as 
variant CJD (vCJD). It occurred in younger patients compared to those with 
the sporadic form of CJD and its epidemic peaked in 2000/2001 (Table 2) 
(Will et al., 1996; NCJDRSU). 
  
 
14 
Table 2. Deaths from definite and probable vCJD from the first cases in 1995 up to 2011 (n = 
175) (* Data updated at 7th November 2011). 120 in 175 deaths are from confirmed vCJD, 
whilst 54 in 175 are deaths from probable vCJD, since the neuropathological confirmations 
are pending. There is 1 probable vCJD case still alive (NCJDRSU). 
 
3 - CAUSATIVE AGENT 
3.1 - History 
Despite scrapie, the oldest and most widespread spongiform encephalopathy, 
was known for over than 200 years, its causative agent was identified only at 
the end of the 20th century by an American neurologist, Stanley B. Prusiner 
Year
1995 3
1996 10
1997 10
1998 18
1999 15
2000 28
2001 20
2002 17
2003 18
2004 9
2005 5
2006 5
2007 5
2008 2
2009 3
2010 3
2011* 4
Deaths from definite 
and probable vCJD
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(Prusiner, 1982; Prusiner, 1998), whose studies were awarded the Nobel 
Prize in medicine in 1997. 
During the 20th century different definitions of the causative agent of the TSEs 
and many theories on its nature were put forward, and it was classified 
amongst the Unconventional Infectious Agent. 
In 1966 Alper and colleagues suggested that nucleic acid was not needed for 
replication (Alper et al., 1966; Alper et al., 1967) and the following year the 
mathematician J. S. Griffith was the first to formulate a “prion only” theory of 
scrapie pathogenesis. In 1982, Prusiner was able to extract and purify the 
causative agent from infected tissues, noting with surprise that this was 
nothing more than a constitutive protein, the prion protein (PrP), encoded by a 
host gene and not by a foreign invader. He coined the term “prion”, which was 
(and is) meant to denote a “proteinaceous infectious particle”, to emphasize 
the requirement of a protein for infection. However, at that time, it was not 
sure whether that particle contained nucleic acid or not (Prusiner, 1982; 
Bolton et al., 1982).   
3.2 - Cellular Prion Protein 
The cellular prion protein (PrPC) is a constitutive protein encoded by the Prnp 
gene, highly conserved among mammals (Aguzzi et al., 2004); its  paralogs 
have been revealed in birds (Nuvolone et al., 2009), reptiles (Simonic et al., 
2000), fish (Rivera-Milla et al., 2003) and amphibians (Strumbo et al., 2001). 
At a cellular level, PrPC is synthesized in the cytoplasm, transported through 
the endoplasmic reticulum and Golgi apparatus and displayed on the plasma 
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membrane, which binds by a glycosylphosphatidylinositol (GPI) anchor 
(Ryoux et al., 2007). 
Its broad and diverse expression pattern, with expression in skeletal muscle, 
kidney, hearth, pancreas, secondary lymphoid organs and central nervous 
system (CNS), would point presumably to a general, conserved and broad 
function (Ford et al., 2002; Aguzzi et al., 2004). Within the CNS and peripheral 
nervous system (PNS) PrPC expression levels can be detected in synaptic 
membranes of neurons as well as in oligodendrocytes, Schwann cells and 
astrocytes. In the periphery PrPC expression is reported on lymphocytes and 
importantly at high levels on stromal cell of the immune system: the follicular 
dendritic cell (FDC), located in organs of the lymphoreticular system (LRS) 
(Heikenwalder et al., 2007).  
The PrPC glycoprotein can be either un-, mono- or diglycosylated. Its three 
dimensional structure preserves common features in different species: 
mouse, human, cattle and Syrian hamster. It consists of a long, flexible N-
terminal tail (residues 23-125), which contains a sequence of 8 amino acids 
repeated 5 times. The globular C-terminal domain (residues 126-131) is 
folded to form three α-helices and a short two-stranded anti-parallel β-sheet 
that flanks the first α-helix; it is stabilised by a disulfide bond linking α-helices 
two and three (Riek et al., 1997; Ronga et al., 2006; Moore et al., 2009; 
Heikenwalder et al., 2007) (Figure 2). 
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Figure 2. Model of PrPC structural domains. The folded C-terminal portion of PrPC contains 
the short β-sheet strands and the α-helices. The remainder of the molecule appears to be 
flexibly disordered (Caughey et al., 2001) 
 
 
PrPC has also been named PrPsen, because of its sensibility to proteinase K 
(pK) digestion (Caughey et al., 2001). 
Despite several possible roles of PrPC have been proposed, no one has been 
confirmed (Ryou et al., 2007). PrPC appears to play a role in synaptic plasticity 
(Maglio et al., 2004), lymphocyte activation (Cashman et al., 1990; Ryou et 
al., 2007), response to oxidative stress (Milhavet et al., 2002), signal 
transduction (Mouillet-Richard et al., 2000) and metabolic functions related to 
copper-binding properties (Brown et al., 1997; Watt et al., 2003; Ryou et al., 
2007). PrPC is also seems to be involved in differentiation and neurogenesis 
of neuronal stem cells (Steele et al., 2006) as well as long-term renewal in 
haematopoietic stem cells (Zhang et al., 2006). 
However, independent studies with several different PrP null mouse strains 
have not found any major impairment as well as distinct physiological and 
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behavioural changes, suggesting that PrPC might be not essential to the 
development and survival (Bueler et al., 1992). 
Although the function of PrPC in animal physiology is ambiguous, its 
involvement to the pathogenesis of prion disease is clearly understood. 
Expression of PrPC is a prerequisite to demonstrate a susceptibility of prion 
diseases in the hosts. Research has demonstrated that is not possible to 
transmit the disease when prions are inoculated in PrP-deficient mice, while 
the incubation time of disease become shortened when prions are transmitted 
to the transgenic mice, over-expressing PrPC in the brain at least several 
times higher than wild-type mice (Bueler et al., 1992; Fischer et al., 1996; 
Ryou et al., 2007). 
3.3 - Post-translational changes of the prion protein   
The cellular prion protein undergoes post-translational modifications that take 
place in the plasma membrane within the lipid rafts (see below) (Tellier et al., 
2006). PrPC is cleaved by an α-secretase inside its sequence 106-126 
(residues 110/11-112), leading to the production of N1 and C1 fragments. 
That proteolysis is mediated by two distinct metalloprotease, a constitutive 
one, ADAM (A Disintegrin And Metalloprotease) 10, and an inducible one, 
ADAM 17 or TACE (Tumor necrosis factor Alpha-Converting Enzyme), which 
prevent the prion protein from the toxic conversion (Vincent et al., 2001; 
Checkler et al., 2002; Walmsley et al., 2003; Tobias et al., 2003; Vincent, 
2004; Laffont-Proust et al., 2005; Ronga et al., 2006; Parkin et al., 2007). 
Then PrPC moves out of the lipid rafts, in order to be endocytosed via clathrin-
coated pits (Sunyach et al., 2003; Schengrund et al., 2010). 
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In pathological conditions instead, PrPC in the lipid rafts is cleaved by an 
unknown protease, that acts 20 amino acids upstream of the ADAM-cleavage 
site (residues 90-91), generating the N2 peptide and leaving the 106-126 
domain intact, considered potentially toxic because of its tendency to fold into 
β-sheets, making inaccessible the binding sites to the pK and therefore 
insoluble the protein (Vincent et al., 2001; Checkler et al., 2002; Walmsley et 
al., 2003; Tobias et al., 2003; Vincent, 2004; Laffont-Proust et al., 2005; 
Ronga et al., 2006; Parkin et al., 2007). 
3.4 - Protein misfolding 
The toxic conversion of the prion protein to prion (PrPSc), causes the onset of 
the TSEs and its detection is considered pathognomonic for TSEs diagnosis. 
The soluble, protease sensitive form of PrP (PrPC) is refolded and converted 
into an insoluble protease-resistant form, the prion (PrPSc). PrPSc has the 
same primary sequence as PrPC but a different secondary structure. Thus, 
where PrPC is higher in α-helical content, PrPSc is higher in β-sheet content. 
The misfolding may be due to a sporadic or inherited genetic mutation or may 
be acquired, as a result of ingestion of prions, able to  induce an allosteric 
conformational change in PrPC. 
That process is still poorly understood (Moore et al., 2009), even though it 
seems likely that toxic conversion may requires the presence of one or more 
cofactors, able to mediate the interaction between the two isoforms of the 
prion protein (Colby et al., 2011).  
The different three-dimensional conformations of PrPC and PrPSc give them 
different biochemical and biophysical properties (Ryou et al., 2007) (Table 3). 
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Table 3. Properties comparison between PrPC and PrPSc (Modified from Ryou et al., 2007). 
Properties PrPC PrPSc 
Protein Normal, cellular protein Disease-associated protein 
Infectivity No infectious Infectious; pathogenic 
Folding Dominated by alpha-helices Beta-sheet abundant 
conformation 
Solubility Easily soluble (hydrophilic) Insoluble (hydrophobic) 
Protease digestion Sensitive Partially, but highly resistant 
 
Prion indeed has its own characteristics. The pK, which fully digest PrPC, 
usually removes only the N-terminal third (~ 6-8 kDa) of PrPSc. Moreover, 
PrPSc is resistant to high temperatures, relative high pressure, formaldehyde 
treatment and UV-irradiation (Caughey et al., 2001; Heikenwalder et al., 2007 
Ryou et al., 2007) 
After PrPC toxic conversion, PrPSc amplifies and aggregates in amyloid fibrils, 
which can accumulate inside and outside the cell and are responsible for the 
formation of amyloid plaques, gliosis, vacuolisations and neuronal death by 
apoptosis. The prion protein localization in lipids rafts (see below) appears 
important in allowing its misfolding and the progression of clinical disease 
(Pinheiro, 2006). 
3.4.1 - Lipid rafts 
Traditionally the structure of biological membranes has been defined 
according to the fluid mosaic model (Singer et al., 1972). In this model the 
different species of lipids form a homogenous mixture in which membrane 
proteins are uniformly dispersed. More recent data, however, indicate that 
there is heterogeneity in biological membranes (Engelman et al., 2005), with a 
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growing body of evidence supporting the existence of specialised lipid 
domains, including cholesterol- and sphingolipid-rich lipid rafts (Simmons et 
al., 1997). The main constituent of plasma membrane are phospholipids, 
sphingolipids and cholesterol. Pure sphingolipids pack tightly together as their 
saturated acyl chains allow close interaction and form a gel-like phase. This is 
in contrast to the loose packing of phospholipids, whose kinked unsaturated 
acyl chains preclude closer interaction. This differential packing ability leads to 
a phenomenon known as phase separation when the two types of lipid are in 
a membrane, with sphingolipids forming a gel-like phase and phospholipids a 
liquid-disordered phase. Cholesterol preferentially interacts with sphingolipids 
and shift the gel-like phase of pure sphingolipids to a more fluid liquid-ordered 
phase, which equates to the lipid rafts (Taylor et al., 2007). 
Numerous proteins implicated in cellular homeostasis are located within them 
and it is clear that lipid rafts are important regulators of cellular activity 
(Garattini, 2007; Ma et al., 2004). They are indeed  involved in a range of 
biological processes, including intracellular trafficking, transmembrane 
signalling, lipid and protein sorting, vital uptake and regulated proteolysis. In 
addition, lipid rafts are a site of attack for many pathogens (Taylor et al., 
2007). 
There is compelling evidence that lipid rafts provide a membrane environment 
conducive to prion conversion. However, it is currently unclear exactly what is 
about rafts that favours conversion. Three hypothesis have been suggested. 
Lipid rafts may provide a mean to target PrPC and PrPSc to intracellular 
compartments that favour conversion. Another potential explanation assumes 
the presence in that domains of cofactors able to facilitate the prion 
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misfolding. The third hypothesis suggests that lipid rafts create an 
environment conducive to toxic conversion destabilizing the α-helix structure 
within the prion protein (Pinheiro, 2006; Taylor et al., 2007) (Figure 3). 
Figure 3: Models for how lipid rafts provide a favourable site for PrPSc formation. (A) Lipid 
rafts (pink membrane) provide a platform by which PrPC (blue) and PrPSc (red) are targeted to 
intracellular sites that favour conversion. (B) Rafts contain a co-factor (yellow triangle) that 
facilitates conversion of PrPC to PrPSc. (C) The predominantly α-helical structure of PrPC is 
destabilised when PrPC transits through non-raft regions (white membrane) giving rise to a 
misfolded intermediate (green). When this misfolded intermediate enters a raft environment it 
is a better substrate for PrPSc-mediated conversion (Taylor et al., 2007). 
 
3.5 - Species barrier 
To limit the infectivity of PrPSc there is the so called “species barrier”, a 
phenomenon responsible for the lower efficiency in interspecies than 
intraspecies transmission of the prion diseases. 
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To cross the species barrier there must be a sufficient homology in the 
primary and secondary structures of the middle third of the prion protein 
(residues 108-189) between exogenous PrPSc from one species and 
endogenous PrPC of another species. In the rare cases where prion 
transmission is possible between different species, it occurs only after 
prolonged incubation times (Caughey et al., 2001; Ryou et al., 2007; Moore et 
al., 2009). The shortest incubation times (the interval between inoculation and 
clinical signs of disease) are achieved with intracerebral inoculation of prions 
with an amino acid sequence identical to that of the host animal. When the 
donor prion originates from a species different from the host animal and thus 
the sequences differ between infecting PrPSc and PrPC, the incubation time 
can be prolonged and vary substantially between individual animals 
inoculated; often, many of the inoculated animals do not develop disease. 
Variation in PrP sequences indeed exist not only between species but also 
between individuals within the same species, greatly affecting the 
susceptibility to prion infection (Pattison et al., 1965; Colby et al., 2011). 
4 - TSEs PATHOGENESIS IN RUMINANTS 
The pathogenesis of TSEs in sheep and cattle is very similar. The causative 
agent is the prion and the infection usually occurs by the oral route. In scrapie 
the infectious agent is present in the environment and taken up orally during 
grazing on scrapie contaminated pastures. In the case of BSE in cattle, 
infection has occurred through feeding concentrates with MBM derived from 
BSE infected cattle (Van Kuelen et al., 2008). 
  
 
24 
It is still obscure how TSE agents cross the mucosal barrier after they are 
ingested, but here are three possible ways (Figure 4).  
Figure 4. Schematic representation of the possible ways of intestinal epithelial crossing and 
subsequent invasion of the enteric nervous system. After ingestion, PrPSc can be taken up by 
M-cells (1) or dendritic cells (2) and transported to the lymphoid follicles (LF) of the Peyer’s 
patches underlying the follicle-associated epithelium (FAE). Within the lymphoid follicles PrPSc 
accumulates on follicular dendritic cells and is taken up by follicular macrophages. This 
accumulation of PrPSc could facilitate infection of the neighbouring submucosal plexus of the 
enteric nervous system. Alternatively, PrPSc could be taken up as a complex with ferritin and 
transcytosed by intestinal epithelial cells through the ferritin pathway (3). Once the epithelium 
is crossed, the mucosal plexus of the enteric nervous system can get infected followed by 
neural spread to the submucosal plexus (Van Kuelen et al., 2008). 
 
 
The first is through the membranous epithelial cells (M-cells), a cell type 
present in the follicle-associated epithelium of the gut and tonsil which 
specializes in transport of macromolecules and particles across the epithelium 
(Heppner et al., 2001). It has been shown for prions, viruses and bacteria that 
M-cells can be used by pathogens to cross the mucosal barrier and gain 
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access to underlying tissues (Neutra et al., 1996). However, transport of TSE 
agent across the gut epithelium could also occur independent of M-cell 
transport. Digestive enzymes can break down the infectious agent into smaller 
molecules of PrPSc or even into the protease resistant core of PrPSc. Such 
smaller fragments can then form complexes with other proteins like ferritin 
and get endocytosed in vesicular structures by a ferritin dependent 
mechanism (Mishra et al., 2004). A third possible route could be through 
direct uptake by dendritic cells that can open up the tight junctions between 
epithelial cells and capture antigens by inserting their dendritic processes into 
the gut lumen (Rescigno et al., 2001 a; Rescigno et al., 2001 b). This had 
been demonstrated for bacteria but has yet to be shown for TSE agent (Van 
Keulen et al., 2008). 
After crossing the mucosal barrier, infectivity and PrPSc first accumulates in 
the gut-associated lymphoid tissues (GALT) of the tonsil and the Peyer's 
patches in the intestines (Aguzzi et al., 2003). This initial accumulation in the 
GALT strongly favours the hypothesis of transport of TSE agents through M-
cells, because antigens that have been transcytosed by M-cells are actively 
transported from the basal side of the M-cells to the underlying GALT by 
either dendritic cells or macrophages. 
Then the neuro-invasion occurs and prion reaches the enteric nervous system 
(ENS) of the gut (Terry et al., 2003; Van Keulen et al., 2008). The ENS is the 
intramural nervous system of the gut and is composed of two major networks 
or plexuses, which contain the neuronal cell bodies (also called ganglion cells) 
and their processes. These two major plexus are the submucosal or 
Meissner's plexus, located in the submucosa, and the myenteric or 
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Auerbach's plexus, located between the circular and longitudinal muscle 
layers (extending from the esophagus to the rectum). In addition to these two 
major plexus there are minor plexus in the serosa, circular muscle layer and in 
the mucosa, that contain no or few ganglion cells but consist mainly of small 
nerve fibres. Although the ENS is capable of functioning independently, it is 
modulated by the CNS by means of the parasympathetic and sympathetic 
efferent nerves of the autonomic nervous system that are connected to the 
nervous system. The cell bodies of the preganglionic parasympathetic 
neurons are located in the dorsal motor nucleus of the vagus (DMNV) in the 
medulla oblongata while the preganglionic sympathetic neurons lie within the 
intermediolateral column (IMLC) in the spinal cord. After infection of the ENS, 
TSE agent ascends through these parasympathetic and sympathetic efferent 
neuronal pathways to the brain and (via the ganglion mesentericum 
craniale/coeliacum) to the spinal cord. Portal of entry of TSE agents in the 
brain is thus the DMNV in the medulla oblongata at the level of the obex and 
the IMLC in the thoracic segments of the spinal cord. From these sites in the 
CNS, infection spreads in both an ascending and descending directions to 
finally involve the entire neuroaxis (Van Kuelen et al., 2000; Hoffmann et al., 
2007; Van Keulen et al., 2008). 
In cattle PrPSc accumulates only in the GALT tissues of the Peyer's patches in 
the ileum and in the tonsil of experimentally infected animals and its 
replication in these lymphoid tissues is minimal to absent. From here, except 
for the neuro-invasion, prion does not spread neither through the rest of the 
body nor into the environment, making cattle dead-end host for BSE (Van 
Keulen et al., 2008). 
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Contrary to BSE in cattle, prion in sheep naturally colonizes the GALT tissues 
of the Peyer's patches and the tonsils, where it replicates and spreads not 
only via nervous route but also by lymphatic and haematogenic dissemination.  
Despite the fact that infectivity has never been found in any secreta or excreta 
of scrapie infected sheep, it does not exclude possible low levels of infectivity 
in milk, saliva, faeces or urine, since PrPSc has been found in ectopic 
lymphoid tissue in the mammary gland (Ligios et al., 2005), in the renal 
papillae and in the salivary glands (Vascellari et al., 2007) of scrapie-infected 
sheep. The environmental contamination, that occurs even through the 
infected placentas shedding after lambing, and the direct contact between 
animals make scrapie an endemic disease, meaning that its causative agent 
transmits under natural conditions (Baylis et al., 2002; Van Keulen et al., 
2008). 
4.1 - Scrapie and BSE in ruminants 
Scrapie, a common disease among sheep and goat, is the oldest TSE known. 
It is characterised by a long incubation period, behavioural and neurological 
disorders and inevitable death. It has been found in many countries and it is 
endemic in the UK, while it has been eradicated in New Zealand and 
Australia, thanks to rigorous control and preventive measures. 
Affected animals are adults, the incubation period ranges from 2 to 5 years 
and the clinical course of the natural disease ranges from 8 to 24 weeks in 
sheep and from 2 to 24 weeks in goats (Hunter, 2003; Scanziani et al., 2006; 
CFSPH, 2007). 
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Clinical signs often begin with unusual social behaviour and extreme nervous 
reactions to stimuli such as human contact. The general condition of the 
affected animal deteriorates, sometimes accompanied by a change in the 
fleece colour and often it is this latter feature that is first noticed by the farmer 
or shepherd. Ataxia is common and pruritus can result from the animal 
scratching an apparently intense itch against fence posts or by biting the 
affected area, for example around the base of the tail and occasionally the 
whole of the side of the body can be denuded of wool. In the final stages of 
the disease, although the appetite may appear normal, the animals lose the 
ability to feed themselves and the condition degenerate. Scrapie does not 
seem to alter reproductive ability until muscle wasting interferes with the 
ability to move. Lambs can, therefore, be born successfully to mothers in the 
clinical phase of the disease and rams remain fertile and active even when 
affected by ataxic signs (Hunter, 2003). 
BSE owes its fame to the epidemic which broke out in the UK since the mid-
eighties and to its zoonotic feature, absent in scrapie (Detwiler, 1992; Brown 
et al., 1998). The most cases were diagnosed in cattle aged between 4 and 6 
years (with a very wide fork: from 20 months to 18 years). Dairy cattle were 
found to be more affected than beef breeds, probably because of differences 
in dietary management. The latter are suckled, often for long periods and are 
not usually fed concentrate rations during their initial period of growth and 
sometimes not at all or at a low rate. By contrast, calves from dairy caws are 
removed from their dam soon after birth and they are initially reared on milk 
substitutes and soon weaned on to a diet of hay and concentrates that often 
contained MBM (Smith et al., 2003; TSE, 2007). 
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Prodromal and early clinical signs of BSE are very unspecific and they may 
take weeks to months to progress to overt clinical disease. Animals lose 
weight and decrease milk production while maintaining the appetite. They also 
show behavioural changes, such as anxiety, nervousness, hyperexcitability, 
aggressiveness, sensory hyperaesthesia, especially with over-reaction 
against light and noise, postural and locomotion changes, such as stiff gait 
and ataxia, muscle spasms and tremors, particularly in the hind limbs 
(Scanziani et al., 2006; TSE, 2007).  
Research demonstrated that cattle parenterally inoculated with the scrapie 
agent developed the disease, producing BSE-like signs, especially locomotor 
abnormalities; it is of importance that just few of them developed the nervous 
form, with aggressiveness and over-reaction, which is generally associated 
with BSE (Cutlip et al., 1994; Konold et al., 2006; TSE, 2007). However, the 
natural infection seems unlikely, since cattle are resistant to scrapie when 
infected orally (Cutlip et al., 2001; TSE, 2007).  
On the contrary, oral transmission of BSE to sheep and goats is possible and 
challenged animals develop a disease with clinical signs that are 
indistinguishable from those caused by scrapie (Foster et al., 1993; Bellworthy 
et al., 2008). Symptoms are intense pruritus, leading to loss of fleece, ataxia, 
weight loss and behavioural changes; these signs become progressively more 
severe over the clinical course of the disease and culminate in death (Baron 
et al., 2000; Baylis et al., 2002).. 
Small ruminants exposure to the causative agent of BSE is a realistic chance, 
since they have been fed with the infected MBM (Wilesmith et al., 1991; Smith 
et al., 2003). Anyway, the amount of infectious material consumed would have 
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been much less than that consumed by cattle. A sheep eats, on average, only 
1-2% of the volume of feed concentrate eaten by a bovine and the amount of 
MBM in sheep concentrate was at most equal to, and probably much less 
than, that present in the cattle equivalent. Sheep, then, were much less 
exposed to BSE than were cattle (Kao et al., 2002; Baylis et al., 2002). 
However, the species barrier that would have prevented the BSE infection of 
small ruminants, making the exposure to high titers of PrPSc required for the 
occurrence of interspecies transmission, is not effective. In fact, even though 
a 1000 times higher infective dose of cow-derived BSE causative agent is 
required to kill a mouse than a cow (Wells et al., 1998), BSE species barrier 
from cattle to genetically susceptible sheep appears to be very small or even 
non-existent. An experimental study showed indeed that low infectious doses 
(0-5 g) orally administrated to sheep are enough to transmit BSE (Foster et 
al., 1993). The absence of the scrapie barrier is one of the evidences 
supporting the hypothesis that BSE is a cattle-adapted form of scrapie (Baylis 
et al., 2002). 
The gene responsible for control of susceptibility and resistance to TSEs is 
the Prnp and, in sheep, the most important amino acids are at numbers 136, 
154, 171. At codon 136, the amino acid specified can be either valine (V) or 
alanine (A), at codon 154 it is arginine (R) or histidine (H) and, at codon 171, 
arginine (R), glutamine (Q) or histidine (H). Of the twelve possible alleles 
derivable from these polymorphisms, only five are commonly seen: 
A136R154R171 (hereafter ARR), ARQ, VRQ, AHQ and ARH (Belt et al., 1995). A 
sheep contains two such alleles and the combination (i.e. ARR/VRQ) is called 
PrP genotype. Sheep with the ARR/ARR genotype are highly or completely 
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resistant to classical scrapie, while sheep with the VRQ/VRQ genotype are 
most susceptible. The ARQ/ARQ genotype is the highly susceptible to BSE in 
sheep (Baylis et al., 2002; Hunter et al., 2003; CFSPH, 2007) (Table 4).   
Table 4. Prion protein polymorphism and the five commonly found PrP gene alleles in sheep 
(Hunter et al., 2003). 
 
Retrospective studies have recently identified two cases of natural BSE in 
field goats, in France (Eliot et al., 2005) and in the UK (Spiropoulos et al., 
2011). PrPSc in small ruminants affected with BSE has been found not only in 
the CNS, but also widely distributed in the lymphoid tissues (lymph nodes, 
spleen, tonsil and Peyer's patches) and the PNS. This distribution contrasts 
dramatically with that seen in cattle BSE and is very similar to the distribution 
seen in natural scrapie, where the broad tissue tropism is considered the main 
factor responsible for the sheep-to-sheep transmission (Foster et al., 2001; 
Codon number Amino acid Allele
136 Valine (V) VRQ
Alanine (A) ARQ
ARR
AHQ
ARH
154 Arginine (R) VRQ
ARQ
ARR
ARH
Histidine (H) AHQ
171 Glutamine (Q) VRQ
ARQ
AHQ
Arginine (R) ARR
Histidine (H) ARH
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Baylis et al., 2002). The similar wide distribution in peripheral tissue would 
retain BSE infectivity within a flock also after the elimination of the initial 
source of infection. Recent evidences confirm that BSE can be transmitted 
naturally between sheep (Bellworthy et al., 2005). 
5 - NEURODEGENERATION IN PRION 
DISEASES 
The inevitable consequence of prion infection is neurodegeneration. 
The extraneuronal accumulation of PrPSc in the CNS lead to microglia 
activation, which respond to the neurotoxic PrP 106-126 pepide by producing 
pro-inflammatory cytokines, interleukin 1β and interleukin-6 (Perry et al., 
2002; Kovacs et al., 2008; Hughes et al., 2010). Microglia represent the 
largest population of phagocytes in the CNS and have a principal role in 
immune defence and inflammatory responses there (Hughes et al., 2010). 
Microglia are referred to as activated as judged by their altered morphology 
and the upregulation of cell surface antigens, including major 
histocompatibility complex class II, and a number of cytosolic and endosomal 
antigens. The microglia activation occurs early in prion disease and indeed is 
one of the few pathological markers that is associated with the early onset of 
behavioural dysfunction (Perry et al., 2002). Even though there are apparent 
robust evidence not only of microglial but also of astroglial activation in TSEs, 
the failure to clear the abundant amyloid deposition suggest that phagocytosis 
is somehow deficient in these diseases (Hughes et al., 2010) and inversely 
may contribute to neuronal death and formation of spongiform change 
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(Rezaie et al., 2001; Kovacs et al., 2008). Spongiosis is the main 
neuropathological feature associated to TSEs observed in histological 
analysis of affected brains and is characterised by small (< 10µm) round or 
oval vacuolization of the neuropil. These vacuoles must be distinguished from 
vacuoles commonly seen in late stages of various neurodegenerative 
disorders and from other irregular vacuoles caused by tissue rarefaction or 
edema. The exact mechanism of spongiform change in prion diseases is still 
not clear, but it is likely a result of abnormal membrane permeability and 
increased water content within neuronal processes or it may be also result 
from autophagy (Kovacs et al., 2008). Neurodegeneration in prion diseases 
eventually lead to neuronal death by the apoptotic pathway (Kovacs et al., 
2008). 
6 - DIAGNOSIS 
Historically, techniques used to diagnose TSEs were designed to detect, in 
appropriate tissue samples, lesions characteristic of TSE or the transmissible 
agent itself (Grassi et al., 2008). 
Both BSE and scrapie occur as different types and strains. Types are 
recognised basing on PrPSc-banding pattern in Western blot, while strains of 
TSEs are defined by their phenotypic behaviour after cloning the isolate in 
rodents, although the original isolate phenotype frequently is strain indicative 
(Jacobs et al., 2011). 
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6.1 - Histology and immunohistochemistry 
Histological detection of lesions typical of TSE (spongiosis, astrogliosis, 
amyloid plaques), essentially in the CNS, is the reference method for 
confirming a clinical diagnosis. It is very specific, since it allows direct 
observation of the signs of the disease, but it is less sensitive than other 
techniques (Gavier-Widen et al., 2005; Grassi et al., 2008). The sensitivity of 
microscopic observation can be increased by immunohistochemical 
techniques that use antibodies specific to PrP to detect accumulation of PrPSc 
in amyloid deposits (van Kuelen et al., 1995; van Kuelen et al., 1996). This 
technique efficiency depends greatly on sample preparation and on the nature 
of the antibodies used (Grassi et al., 2008). 
Although these methods are ill-suited to rapid, routine analysis, they are 
excellent for confirmation (Grassi et al., 2008). They are also effective for the 
analysis of samples of lymphoid tissues (tonsils, Peyer's patches, lymph 
nodes) and can be utilised, for example, in preclinical diagnosis of scrapie in 
sheep (van Kuelen et al., 1996; Andréoletti et al., 2000) and CWD (Spraker et 
al., 2002). These diseases are characterised by marked replication of the 
prion in the lymphoid organs during the presymptomatic phase.  
6.2 - Western blot 
Western blot (WB) has been used to detect PrPSc in tissue extracts for 25 
years (Bendheim et al., 1986). 
Since all samples always contain PrPC, the protease-sensitive prion protein, 
they are systematically treated with pK. After denaturation of the tissue extract 
by heating with sodium dodecyl sulfate (SDS), it is analysed by 
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polyacrylamide gel electrophoresis (PAGE) and the denatured protein is 
transferred to a solid support and detected with an enzyme-labelled antibody. 
The specificity of WB stems, among other things, from the fact that proteolysis 
with pK characteristically alters the molecular weight of the PrPSc, because of 
the partial degradation of the N-terminal part of the protein. As a 
consequence, in addition to the residual signal observed, the gel bands shift 
in a manner typical of PrPSc (Grassi et al., 2008). The resistant part PrPSc can 
be observed by WB usually in the 17-30 kDa region as a triple band, 
representing the di-, mono- and unglycosylated PrP isoform (Jacobs et al., 
2011). 
6.2.1 - TSE types in cattle and small ruminants 
In cattle C-type, L-type and H-type BSE have been recognised (Jacobs et al., 
2011). The definition of L-type and H-type BSE is according to the higher and 
lower position of the unglycosylated PrPSc band in WB, respectively, 
compared to the position of the band in classical BSE (C-type) isolates 
(Jacobs et al., 2007) (Figure 5). 
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Figure 5. Results of WB analysis of L-, C-, and H-type BSE isolates with antibody L42. (A) 
Lanes with L-, C-, and H-type material with tissue equivalents of 0.5, 0.2, and 0.2 mg, 
respectively, placed between molecular mass marker lanes. (B) Apparent molecular masses 
of diglycosylated (circles), monoglycosylated (squares), and unglycosylated (triangles) bands 
with standard deviations for L-type (n  11), C-type (n  9), and H-type (n 6) isolates. Arrow = 7-
kDa band (Jacobs et al., 2007). 
 
 
In small ruminants four TSE types have been recognised based on PrPSc-
banding patterns: classical scrapie, Nor98 scrapie (a form of atypical scrapie), 
BSE and CH1641 scrapie. The unglycosylated band of classical scrapie has a 
molecular weight of 18-19 kDa. Nor98 scrapie is characterised by a main 
PrPSc band at 7-8 kDa (Jacobs et al., 2011). The unusual scrapie isolate 
CH1641 and PrPSc that causes BSE (C/L-type) have unglycosylated bands 
with similar molecular weights (16-17 kDa), which are lower than the 
molecular weight of the PrPSc that causes typical scrapie. Furthermore, 
CH1641 prions have a protein fragment produced by the C-terminally 
cleavage of PrPSc, designed as PrPSc #2 (molecular weight, 14 kDa), which 
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permits to differentiate between CH1641 scrapie and BSE (Hope et al., 1999; 
Baron et al., 2008; Yokoyama et al., 2010). 
6.3 - Experimental infection tests 
The most sensitive and specific method of diagnosing TSE is unquestionably 
experimental infection in laboratory animals, classically rodents and in most  
cases of murine species. Animals are injected, usually by intracerebral route, 
with a homogenate prepared from the potentially infected tissue and are 
watched for the appearance of clinical signs. After their death, disease 
development is confirmed using classic techniques: histology, 
immunohistochemistry and WB (Grassi et al., 2008). 
The mouse bioassay with wild-type strains (C57Bl, RIII and VM) is the gold 
standard model for assessing the biological properties of prions and the 
discrimination of TSE strains (Bruce et al., 2002; Beck et al., 2010 b). 
Recently, the availability of transgenic mice has broadened the border of 
research.  
PrP knockout mouse model, in which the physiological protein is genetically 
ablated, led to the awareness that the PrPC expression is indispensable to the 
developing of TSEs and was utilised to investigate the physiological role of 
PrPC (Groschup et al., 2008). 
Moreover, the availability of transgenic mice that overexpress the same PrP 
as that of the donor species has significantly increased the efficiency of 
experimental transmission and shortened incubation period (Grassi et al., 
2008; Simmons et al., 2008). Mutant PrP expression mouse models have 
contributed enormously to a better understanding of the nature of prions, 
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allowing to study the molecular aspects of species barrier effects, the cell 
specificity of the prion propagation, the role of the PrP glycosylation, the 
mechanisms of the prion spread and the neuropathological roles of PrPC and 
of its abnormal isoform PrPSc. Transgenic mouse models have also been 
used for mapping of PrP regions involved in or required for the PrP 
conversion and prion replication as well as for modelling of familial forms of 
human prion diseases (Groschup et al., 2008). 
However experimental infection tests are too labour-intensive and time-
consuming for use in routine high throughput screening (Grassi et al., 2008). 
6.3.1 - Incubation period and lesion profile 
The agents causing TSEs exhibit clear evidence of strain variation. Studies of 
mouse-passaged TSE isolates have established that the phenotype of the 
disease depends on an interaction between the strain of TSE agent and 
genetic factors in the host (Dickinson et al., 1971; Bruce et al., 1991; Bruce et 
al., 2002). These observations led, many years ago, to the development of 
formal TSE strain typing methods, that depend primarily on the measurement 
of incubation periods (Dickinson et al., 1968) and construction of “lesion 
profiles” in panels of defined mouse strains. The lesion profile is a 
semiquantitative representation of severity and distribution of vacuolar 
degeneration in the brains (Fraser et al., 1968). Each panel of mice must be 
formed by at least five clinically and pathologically positive animals, to 
compensate individual variations (Beck et al., 2010 b). Using these methods, 
numerous distinct laboratory strains of TSE agents have been identified, with 
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signatures that remain stable over many serial mouse-to-mouse passages 
(Bruce et al., 1991; Bruce et al., 2002). 
The mouse lines used were the wild-type ones, such as RIII and C57Bl, which 
share the same Prnp amino acid sequence (Prnpa), and VM, which differ at 
codons 108 and 109 (Prnpb) (Westway et al., 1987). This difference in 
genotype affects both the incubation period and lesion profile of specific 
isolates (Bruce et al., 1991; Bruce et al., 2002; Beck et al., 2010 b). 
6.3.1.1 - BSE and scrapie  
After primary transmission of BSE or scrapie, RIII mice had shorter incubation 
periods than C57Bl ones (Bruce et al., 2002). 
The BSE lesion profile has a great stability, both after interspecies or 
intraspecies transmission (Bruce et al., 1994). 
On the primary isolation in mice, BSE gives rise to a characteristic lesion 
profile, characterised by peaks in vacuolation score in the dorsal medulla, the 
hypothalamus and the septum. On subsequent subpassages it differs in two 
stable strains, 301C and 301V, depending on the PrP genotype of the host 
(Prnpa o Prnpb) (Bruce et al., 2002; Beck et al., 2010 a). 
The BSE “signature” has been found in the lesion profile produced by the 
causative agent of vCJD, revealing the zoonotic potentiality of BSE (Bruce et 
al., 1997; Hill et al., 1997), and has been recognised also in other animal 
species, providing evidence that these species have been infected 
accidentally with BSE (Bruce et al., 1994). 
On the contrary, on primary isolation scrapie generates lesion profiles that are 
highly variable from each other and distinct from the BSE profile (Beck et al., 
2010 a). The most common ones are 87A and ME7, in mice having Prnpa  and 
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87V and 111A in case of Prnpb (Bruce et al., 2002). Natural scrapie infection 
is cause by multiple prion strains and the resultant phenotype depends on 
which prions are dominantly propagated in a given host. The reason why 
multiple prion strains emerged during inter- and intraspecies transmission, 
even amongst animals with the same Prnp, is still unclear (Yokoyama et al., 
2010). 
One possible explanation for the different behaviours of these two TSE agents 
may be that the BSE agent has emerged recently and is able to cross species 
barriers without any alteration of its biologic properties. In contrast, scrapie is 
highly adapted to sheep and different strains of the agent may have evolved 
over time and adapted to several host-specific factors, the most important 
being the PrP genotype (Beck et al., 2010 a), which presents an high 
variability in sheep (Begara-McGorum et al., 2002; Bruce et al., 2002; Hunter 
et al., 2003). 
6.3.2 - Immunohistochemistry 
Lesion profiles have historically provided the most informative method of 
strain characterization through the bioassay. However, since different strains 
may give rise to unique patterns and types of PrPSc deposition in the mouse 
brain, attention has more recently turned to the use of immunohistochemistry 
for identification and characterization of strains. Early indicators suggest that 
this method could offer greater sensitivity and the capability of identifying 
agent strains at the level of individual mice compared with lesion profiling, 
which requires an average profile plotted from at least five clinically and 
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pathologically positive mice, because of variation in individual mouse profiles 
(Brown et al., 2003; Beck et al., 2010 b). 
6.4 - Rapid tests for post-mortem diagnosis of TSE 
None of the abovementioned methods are really suited to high-throughput 
screening of TSEs and cannot be automated. After the 1996 mad cow crisis 
and the fear of possible transmission to humans, it became clear that there 
was a need to develop new simpler and faster diagnostic tests for large-scale 
epidemiological studies and more accurate assessment for the characteristics 
of the epizootic or for routine testing to warrant safety of animal meat, for 
instance, of all cattle before they enter the food chain or industrial circuits. A 
new generation of so-called “rapid” diagnostic tests emerged, all based on the 
immunological detection of PrPSc, the only identified reliable marker of TSE. 
Again, due to the absence of antibodies that specifically recognise PrPSc, it 
was necessary to resort to indirect approaches to distinguish between the two 
isomers of PrP on the basis of their biochemical properties, such as the well-
known resistance to pK degradation. 
The first three rapid tests approved by European Commission in May 1999 
were product respectively by Prionics (Zurich, Switzerland), CEA (Saclay, 
France) and Enfer Technology Ld (Newbridge, Ireland) (Grassi et al., 2008). 
The Prionics test uses an industrial format of Western blot that enables large-
scale analysis (Schaller et al., 1999) and was the first rapid test used in large 
scale epidemiological studies, first in Switzerland (Oesch et al., 2000) and 
then in France (Calavas et al., 2001).  
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The CEA and Enfer Technology Ld tests instead are based on  an 
immunoenzyme approach (enzyme-linked immunosorbent assay, ELISA). In 
both cases PrPSc is initially selectively purified using pK, centrifuged and 
denatured. Then in the CEA test (now marketed by Bio-Rad, Hercules, CA, 
USA) it is measured by a two-site (so called sandwich) immunoassay that 
uses two monoclonal antibodies (Grassi et al., 2000), while in the Enfer 
Technology Ld test the solubilised and denatured PrPSc is detected using a 
polyclonal antibody directed against a peptide sequence characteristic of PrP 
(Grassi et al., 2008). All these tests were found to have 100% sensitivity and 
specificity. 
In 2002 and 2004 new rapid tests were approved for the post-mortem 
diagnosis of TSEs in ruminants and most of them work in an ELISA format. 
Today, virtually all testing of cattle and small ruminants is done with the tests 
from Bio-Rad, Prionics, IDEXX and Enfer Technology Ld. All positive results 
recorded using the rapid-tests are confirmed in national reference 
laboratories, essentially using histopathology, immunohistochemistry and 
Western blot (Grassi et al., 2008). 
6.5 - Protein misfolding cyclic amplification  
To facilitate preclinical detections of prions in peripheral tissues, notably 
blood, it was developed an original approach in which PrPSc in sample is 
amplified by means of protein misfolding cyclic amplification (PMCA). In this 
approach, which seeks to mimic pathological processes and is akin to 
polymerase chain reaction used to amplify DNA (but without addition of 
exogenous polymerase enzyme), PrPSc is incubated in the presence of PrPC 
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to allow expansion of aggregates of PrPSc which are then dispersed by 
sonication to generate smaller units and to encourage the formation of new 
aggregates. The quantity of PrPSc formed depends on the number of 
expansion/sonication cycles performed (Saborio et al., 2001; Soto et al., 
2005). Amplification is achieved by using as a source of PrPC a brain extract 
from the same species as that which produced the PrPSc to be amplified. This 
method is effective in various mammalian species, including mice, sheep, 
goats and cattle, cervids and humans (Soto et al., 2005; Jones et al., 2007; 
Kurt et al., 2007). PMCA has a great potential and is certainly the most 
promising approach from the view-point of developing a blood test (Grassi et 
al., 2008). 
7 - THERAPY 
On molecular level, prion disease therapeutics can be targeted to PrPC, PrPSc 
or to the process of conversion between the two prion protein isoforms. 
Targeting PrPSc, the disease-associated isoform, may appear to be the most 
logical approach, but such targeting may have no effect on disease 
progression, or even enhance or prolong disease if PrPSc is a non-
pathological end-point of the pathogenic conversion process, or if the rate of 
PrPSc deposition is critical to disease progression (Trevitt et al., 2006). Recent 
evidence indeed suggest that small quantities of the abnormal form of the 
prion protein may not always necessarily be pathogenic and that there might 
be silent prions lying dormant in healthy brains (Yuan et al., 2006; Kovacs et 
al., 2008). Alternatively, targeting PrPC has the potential to remove the 
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substrate for the pathogenesis and is applicable regardless of the disease 
aetiology (Trevitt et al., 2006). 
Several compounds acting at these levels have been studied, but none of 
them seems to have a fully resolving activity. 
The sulphated polyanions and the sulphated glycans are polyanionic 
compounds that manage to delay the onset of the clinical signs in animals 
experimentally challenged with the prion protein, but to be effective they must 
be administrated before or immediately after the infection.  
Amongst the sulphated polyanions the most studied one is the Congo Red 
(CR), a stain used in histology to detect the amyloid deposits. Some studies in 
vitro and in vivo demonstrated its efficacy in preventing  prion accumulation, 
but because of its carcinogenic and teratogenic effects it is not considered a 
safe drug (Caughey et al., 1992; Villa et al., 2003;  Dormont et al., 2003; Poli 
et al., 2004). 
Glycosaminoglycans (GAGs) are the polysaccharide side-chains of 
proteoglycans (PGs), which are component of the extracellular matrix and are 
involved in cell-adhesion, migration and proliferation. GAGs share a common 
architecture, being linear polymers of repeating disaccharide units, including 
an amino-sugar and at least one negatively charged group (sulphate or 
carboxylate). Some of them are sulphated glycans, as heparin sulphate, 
dermatan sulphate, keratan sulphate and chondroitin sulphate. Experimental 
studies demonstrated that they have a direct effect on the conversion of PrP 
and that, depending on the circumstances, they may be either cofactors or 
inhibitors of conversion. In cells they act as a competitive inhibitors of 
endogenous GAGs, putative cofactors of the toxic misfolding of the prion 
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protein, while in cell-free system sulphated glycans are themselves cofactors 
for conversion. The sulphation of these molecules is crucial to their 
involvement with prion conversion, whether as inhibitors or facilitators 
(Caughey et al., 1993; Wong et al., 2001; Dormont et al., 2003; Trevitt et al., 
2006). 
Tetrapyrrolic compounds are known effectors of protein conformational 
change, with structural similarities to CR (being both aromatic and sulphated) 
but with improved toxicological and solubility profiles. In vitro they were found 
to decrease PrPSc levels and to prevent prion propagation. In vivo they 
managed to delay the onset of prion disease after intraperitoneal (i.p.) 
infection, especially following multiple treatments post inoculation, suggesting 
that their mode of action is in peripheral tissues at the initial stage of infection. 
No significant effect was seen either after intracerebral (i.c.) infection or 
administration of the treatment in a late stage of disease (Priola et al., 2000; 
Priola et al., 2003). 
The anti-prionic activity was assessed also in some antibiotics. 
Amphotericin B is a polyene macrolide antibiotic with an antifungal activity. It 
is derived from Streptomyces nodosus, which acts by intercalation into and 
disruption of the cell membrane. It was found to significantly prolong the 
incubation time of prion disease but not to prevent it (Amyx et al., 1984, 
Dormont et al., 2003; Trevitt et al., 2006). 
Tetracycline and doxycicline are tetracyclic antibiotics. Their efficacy against 
experimental scrapie was demonstrated after incubation of the scrapie 
inoculum with drug prior to i.c. infection, which results in a delayed onset of 
disease by reducing the titre of the initial inoculum. They have a 
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decontamination activity rather than a therapeutic one (Forloni et al., 2002). 
Moreover, they were reported to prevent PrP 106-126 peptide-mediated 
cytotoxicity in primary cell culture (Tagliavini et al., 2000) and to reduce 
protease resistant PrP formation in the PMCA replication assay (Barret et al., 
2003).  
Clioquinol, a blood-brain barrier permeable ion-chelating antibiotic, seems to 
be able to reduce the cytotoxic effects induced by copper and to promote the 
solubilization of protein aggregates, reducing the conformational stability of 
PrPSc (Pollera et al., 2005). 
These compounds have not been the only drugs for which the anti-prionic 
activity was tested. 
Quinacrine, a tryciclic compound used as anti-malarial drug, was found to be 
a very efficient inhibitor of PrPSc propagation in infected cells (Korth et al., 
2001). Despite that, quanacrine treatment showed no effect on the incubation 
time of i.c.-infected animals, in either wild-type mice treated orally (Collins et 
al., 2002) or in tg7 mice treated by intra-ventricular infusion. In fact a high 
dose of intra-ventricular quinacrine causes a decrease in scrapie incubation 
time (Doh-ura et al., 2004) and a further study reported that a i.p. quinacrine 
treatment of BSE-infected mice results in an increase in splenic PrPSc 
deposition at 30 days after infection (Barret et al., 2003). 
Chlorpromazine is another tryciclic compound and, as quinacrine, is a drug 
licensed in human for other indications, able to cross the blood brain barrier 
(Dormont et al., 2003). It is less effective than quinacrine in cell culture (Korth 
et al., 2001) but was reported to increase incubation time in mice after i.c. but 
not i.p. infection. These results were published using the compound name 
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aminasine and have not be substained to date (Roikhel et al., 1984; Trevitt et 
al., 2006). 
The statins (lovastatin and squalestatin) are inhibitors of two enzymes of the 
cholesterol synthetic pathway (near the beginning and end of the pathway, 
respectively) and cause a decrease in cellular levels of cholesterol. The 
accumulation of PrPSc in infected cell lines is prevented by treatment of the 
cells with lovastatin or squalestatin. In both cases, this effect is abrogated by 
the addition of cholesterol, suggesting an important role for cholesterol-
sensitive processes in PrPSc formation. It was postulated that the effect of the 
statins is mediated by reducing the amount of PrPC available for conversion to 
PrPSc, by either inaccessibility on the surface, reduced export to plasma 
membrane or increased partitioning to internal compartments (Taraboulos et 
al., 1995; Bate et al., 2004). 
Another compound which was investigated is the curry spice curcumin 
(diferuloylmethane), a planar aromatic small molecule analogous to CR. It is a 
non-toxic antioxidant with antiinflammatory properties (Menonet al., 2007; 
Riemer et al., 2008), which has improved blood-brain barrier permeability 
compared with CR, though is still limited (Trevitt et al., 2006). It was reported 
to inhibit aggregation and promote disaggregation of β-amyloid ( Yang et al., 
2005; Garcia-Alloza et al., 2007;). It is also a potent inhibitor of prion 
replication in cell culture assays (Caughey et al., 2003) while in vivo is able to 
prolong the survival time in a murine prion model (Riemer et al., 2008). 
There are varying reports about the efficiency of immunosuppression as a 
treatment for prion disease. 
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Prednisone and arachis oil are able to delay disease onset following 
administration around the time of i.p. infection, but not following administration 
late in the disease course or after i.c. scrapie-infection (Outram et al., 1974; 
Outram et al., 1975). Non-steroideal anti-inflammatory drugs  were found both 
in neuroblastoma cell lines and primary neuronal cultures to be protective 
against cytotoxicity caused specifically by a prion peptide or by partially 
purified PrPSc preparation from scrapie sick mouse brains (Bate et al., 2002). 
Treatment of scrapie-infected mice with either interferon or interferon  
stimulators had no effect on the disease progression (Allen et al., 1977; 
Gresser et al., 1983; Trevitt et al., 2006). 
Although there is no obvious humoral immune response stimulated in TSEs, 
active and passive immunisations have been tested as putative preventive or 
therapeutic approaches. 
Initial attempts to produce anti-prion antibodies included immunization with 
purified prions or scrapie-associated fibrils (SAFs) with a greater response 
observed in prion knockout mice compared to wild-type mice. Then the use of 
appropriate adjuvants permitted to use recombinant cellular prion protein as 
immunogen in both knockout and wild-type mice (Trevitt et al., 2006). Several 
groups reported moderate beneficial effects, as prolongation of incubation 
time, of active immunization of mice or hamsters with prion protein or peptides 
prior to infection with scrapie isolates (Sigurdsson et al., 2002; Magri et al., 
2005). 
An increase in disease incubation time was reported also after passive 
immunization (Trevitt et al., 2006). 
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Another anti-prion therapeutic approach is based on the use of β-sheet 
breaker peptides, which consist in sequences from the target protein into 
which extra prolin residues are inserted. Prolin in an imino acid unable to take 
the conformation required by an ordered β-sheet structure and its presence in 
a sequence of amino acids residues with otherwise high β-propensity 
prevents the formation of β-sheet by that peptide (Trevitt et al., 2006). The 
design of a β-sheet breaker peptide to specifically interact to prion protein 
conversion (Soto et al., 2000) was spurred by the successful employment of 
β-sheet breaker peptides in models of AD and by the encouraging results 
obtained by Chabry and colleagues (1999). In fact, using prion protein 
peptides of both mouse and hamster sequences (residues 109-141, of which 
119-136 are identical in mouse and hamster protein), they investigated the 
species specificity of conversion and report that both mouse and hamster 
peptides can inhibit toxic conversion of proteins from either species. PrP 116-
136 is also effective in decreasing PrPSc in vitro, whereas other peptides, 
including  PrP 119-128, did not show this effect (Chabry et al., 1999). 
Although most of the studied compounds proved to be promising both in vitro 
and in animal models, none of them was later turned into a useful drug, 
because of toxicity or unfavourable pharmacokinetic properties.  
To date, the only approach which is effective for the prevention of 
symptomatic neurological disease in animals with established prion 
neuropathology is the knockout of neuronal PrPC in transgenic animals 
(Malucci et al., 2003). Although transgenic techniques to ablate the prion gene 
have no direct clinical application at present, RNA interference offers a 
corresponding strategy for PrPC knockdown in vivo (Malucci et al., 2005). 
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RNA interference (RNAi) is the tool by which post-transcriptional gene 
silencing mechanisms in the cell can be initiated. The introduction of small 
double-stranded RNA to a cell leads to the specific degradation of mRNA 
homologous to the introduced RNA molecules. RNAi is thus a means by 
which specific genes can be turned off without the requirement for genomic 
DNA manipulation (Trevitt et al., 2006). Studies in vitro showed that RNAi is 
able to suppress both exogenous and endogenous Prnp expression (Tilly et 
al., 2003) and reduce transiently the level of PrPSc in scrapie-infected cell 
cultures (Daude et al., 2003).  
Research allowed to better understand etiology and pathogenesis of prion 
diseases, even though it has not yet been identified a compound capable of 
providing therapeutic decisive action. 
8 - TSEs AND ALZHEIMER'S DISEASE  
Protein misfolding and amyloid deposition in the CNS are mutual pathogenic 
characteristics of TSEs and Alzheimer's disease (AD). In prion diseases 
proteinaceous deposits are formed by the insoluble, partially protease 
resistant abnormal prion protein isoform (PrPSc). AD is characterised by the 
formation of extracellular insoluble plaques, consisting predominantly of 
amyloid-β (Aβ) peptide of 40-42 amino acids, due to an abnormal cleavage of 
the amyloid precursor protein (APP) (Checkler et al., 2002; Parkin et al., 
2007).  
Both APP and PrPC are cell surface proteins residing in lipid rafts of the cell 
membrane and bear potential toxic sequences (Aβ and PrP 106-126, 
respectively), with the propensity to form β-sheet-rich insoluble and protease-
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resistant fibrils, which undergo a series of proteolytic attacks that are triggered 
by identical proteolytic activities and that are similarly regulated (Checkler et 
al., 2002; Ronga et al., 2006; Hooper et al., 2008).  
Physiologically, both APP and PrPC undergo a cleavage mediated by α-
secretases (ADAM 10 and ADAM 17) inside their toxic core  (Figure 6), while 
in pathologic conditions they both experience alternative cleavages that 
maintain their toxic domains intact. PrPSc seems to derive from a unique 
cleavage of PrPC sustained by an unknown activity. Aβ is produced from APP 
by sequential proteolytic cleavage of β- and γ-secretase (Figure 7). 
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Figure 6. Physiological processing of amyloid precursor protein (APP) and cellular prion 
protein (PrPC). This scheme illustrates the ‘normal’ metabolic pathway for APP (right) and 
PrPC (left). Two distinct disintegrins, ADAM 10 and TACE (tumor-necrosis-factor-α converting 
enzyme, also known as ADAM 17) cleave both proteins inside their toxic sequences (red and 
orange segments). The products are N1 and C1 fragments, and secreted APP (sAPPα) and 
P10, from PrPC and APP, respectively. Interestingly, TACE-mediated processing is strongly 
upregulated by protein kinase C (PKC) agonists, whereas ADAM 10 is responsible mainly for 
the constitutive pathway. Concomitant action of both enzymes results in (1) disruption of Aβ 
and PrPC 106-126 containing fragments, thereby preventing their deleterious effects, and (2) 
secretion of the trophic and neuroprotective product sAPPα. The physiological effects of the 
N1 fragment have yet to be elucidated (Checler et al., 2002). 
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Figure 7: Amyloidogenic and pathogenic processing of APP and PrPC, respectively. The 
schematic representation of βAPP amyloidogenic and PrPC pathogenic pathways 
discriminates between the two-step generation of Aβ (by BACE and γ-secretase) and the 
unique cleavage of PrPC by an unknown activity. Moreover, it is important to note that, 
although Aβ is produced in normal conditions, the C2 fragment is detected only in affected 
brains and never occurs in healthy patients. However, in both cases (1) Aβ and the PrPC 106-
126 containing peptide C2 are generated, and (2) the secretion of the trophic and 
neuroprotective product sAPPα is abolished. The amyloidogenic and/or toxic potency of the 
N2 and C2 fragments have yet to be elucidated (Checler et al., 2002). 
 
 
The β-secretase involved is BACE (β-site APP-cleaving enzyme) 1.  
The γ-secretase is a complex of four different membrane proteins: presenilin 
(PS), believed to contain the catalytic core of γ-secretase, nicastrin, anterior 
pharynx 1 (APH-1), and PS enhancer 2 (PEN-2) (Evin et al., 2006) (Figure 8).  
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Figure 8. The γ-secretase complex comprises four integral membrane proteins. Presenilin 
(PS1 or PS2) is predicted to contain eight or nine transmembrane domains (the eight 
transmembrane structure is represented) and two critical aspartate residues in 
transmembrane domains 6 and 7 that are proposed to form the catalytic site of the enzymatic 
complex. Presenilin becomes proteolytically processed into an N-terminal fragment with six 
membrane-spanning domains, and a C-terminal fragment with two transmembrane domains, 
before becoming inserted into active complexes of high molecular weight. Nicastrin comprises 
a single transmembrane domain and becomes highly glycosylated during maturation of the γ-
secretase complex. The conserved motif DYIGS is important for the recognition of γ-
secretase substrates. APH-1 (named after anterior pharynx defects caused by this gene 
mutation in the worm) is predicted to contain seven transmembrane domains. Alternative 
forms of APH-1 have been described: APH-1a and APH-1b, which are the products of 
homologous genes. APH-1a can be expressed as two isoforms that result from alternative 
splicing of the C-terminal region. Nicastrin and APH-1 can associate as a subcomplex. PEN-2 
(presenilin enhancer) contains two transmembrane domains, and is required for the 
endoproteolysis of presenilin (Evin et al., 2006). 
 
 
This enzyme mediates the ultimate step in the release of Aβ, cleaving APP 
within the membrane. It has no sequence specificity, since it generates Aβ 
peptides of different lengths, but it is conformation specific since it selectively 
binds and cleaves α-helical substrates (Checkler et al., 2002; Evin et al., 
2006). γ-secretase complex cleaves many substrates other than APP, such 
as Notch, essential for normal encephalic functions, and a subset of cell-
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surface receptors and proteins involved in embryonic development, 
haematopoiesis, cell adhesion and cell/cell contacts (Evin et al., 2006). 
There are several similarities between Aβ and PrP. They both have high-
affinity metal-binding sites, which favour the binding of transition metals such 
as copper and zinc, allowing important regulatory functions (Barnham et al., 
2006). In close proximity to these metal-binding sites they have a methionine 
residue (Met35 of Aβ e Met129 of human PrP) that is reportedly essential for 
several activities of both of them. Met35 is thought to modulate Aβ 
neurotoxicity through its crucial role in modulating Aβ redox chemistry and  Aβ 
aggregation. Met129 modulates disease susceptibility in human prion 
disease. Most cases of sporadic CJD occur in homozigotes at codon 129 of 
the human Prnp, where either methionine or valine might be encoded. 
Moreover to date all patients with vCJD have been methionine homozygotes, 
further reinforcing the importance of this residue (Collinge, 2001; Barnham et 
al., 2006). Of potential importance is that the crucial methionine residue is 
located in the putative transmembrane regions of both Aβ and PrP. A 
prominent feature of these transmembrane regions is the presence of several 
repeats of the GxxxG transmembrane-localization motif. The GxxxG motif is 
one example of how the primary sequence regulates peptide and protein 
structure, in this instance by affecting elix-to-elix packing. This packing is a 
key element in defining the tertiary structure of many membrane-bound 
proteins. Both Aβ and PrP contain three repeats of the GxxxG motif: the 
repeat is present in Aβ between residues 25 and 37 (GSNKGAIIGLMVG), 
while the repeat pattern is similar in PrP between residues 119-131 
(GAVVGGLGGYMLG). The crucial methionine of both Aβ and PrP is located 
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in the middle of the last GxxxG repeat (GxMxG). The presence of GxxxG 
repeat motif indicates that PrP, Aβ and/or its parent molecule (APP) are 
probably involved in transmembrane helix-helix interactions, including the 
possible assembly into ion channel-like structure (Barnham et al., 2006). 
TSEs and AD share a number of clinical, pathological and biochemical 
characteristics. The codon 129 polymorphism of the human Prnp was 
reported to affect the number of Aβ deposits in cerebral aging and methionine 
homozygosis at codon 129 was suggested as risk-factor not only for vCJD but 
also for early-onset AD (Zimmermann et al., 1999; Ironside et al., 2004; 
Riemenschneider et al., 2004; Del Bo et al., 2006; Baier et al., 2008).  
It was demonstrated that PrPC expression, when localized in lipid rafts, 
inhibits BACE 1-mediated APP cleavage, markedly decreasing the production 
of Aβ. PrPC N-terminus interacts, through glycosaminoglycans (GAGs), with 
one ore more of the heparin-binding sites on BACE 1 and this interaction then 
restricts access of BACE 1 to its substrate, APP (Parkin et al., 2007; Hooper 
et al., 2008). Controversially, PrPC localised in lipid rafts seems to be a main 
receptor for Aβ oligomers, which bind to amino acid residues 95-110, 
mediating their deleterious effects on synaptic plasticity and function (Laurén 
et al., 2009; Cisse et al., 2009) (Figure 9). 
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Figure 9. Laurén and colleagues (2009) show that Aβ oligomers interact with the membrane-
bound prion protein PrPC. This interaction may in turn disrupt interaction between PrPC and a 
co-receptor, impairing the neuron’s signal-transduction pathways required for synaptic 
plasticity. Alternatively, internalization of PrPC may allow Aβ oligomers to reach intracellular 
compartments, where they might interfere with cellular functions such as protein degradation 
by the proteasome complex, and PrPC-dependent gene transcription (Cisse et al., 2009). 
 
 
Aβ-positive senile plaques in AD patients were found to contain deposits of  
PrPC (Voigtlander et al., 2001; Baier et al., 2008). Recently an in vivo study 
has shown that memory impairment in transgenic mouse models of AD mice 
requires PrPC (Gimbel et al., 2010). Interestingly, the α-secretase enzyme, 
which precludes Aβ production by cleaving the Aβ precursor protein APP 
within the Aβ domain, also cleaves PrPC between residues 111 and 112, thus 
releasing from the membrane the portion of PrPC to which Aβ would otherwise 
bind (Cisse et al., 2009). Also the misfolded PrPSc seems to be involved in the 
fibrillogenesis of Aβ and consequently in the acceleration of disease 
progression (Baier et al., 2008). 
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9 - EUROPEAN LEGISLATION ON TSEs 
After the recognition of the first case of BSE in 1986 in the UK, the EU has 
introduced several laws first to curb the epidemic of the mad cow disease and 
then aimed to TSEs eradication in Europe and to protect animal and human 
health. 
Following there is the chronological list of Community legislation on TSEs 
(Table 5) (European Commission, Food and Feed Safety). 
Table 5. Chronological list of Community legislation on TSEs (European Commission, Food 
and Feed Safety).  
Year Legal text Contents 
1989 
89/469/EEC: Commission Decision of 28 July 1989 
concerning certain protection measures relating to bovine 
spongiform encephalopathy in the United Kingdom (Official 
Journal L 225 , 3.2.1989, P. 51) 
Restrictions on the dispatch of 
certain live cattle from the UK 
1990 
90/59/EEC: Commission Decision of 7 February 1990 
amending Decision 89/469/EEC concerning certain 
protection measures relating to bovine spongiform 
encephalopathy in the United Kingdom (OJ L 41, 15.2.1990, 
p. 24) 
Amendment of Decision 
89/469/EEC - Dispatch 
limitation to only calves under 
6 months old 
  
90/134 EEC: Commission Decision of 6 March 1990 
amending for the second time Council Directive 82/894/EEC 
on the notification of animal diseases within the Community 
and temporarily amending the frequency of notification for 
bovine spongiform encephalopathy (OJ L 76, 22.3.1990, p. 
23)  
Compulsory notification of 
BSE 
  
90/200 EEC: Commission Decision of 9 April 1990 
concerning additional requirements for some tissues and 
organs with respect to Bovine Spongiform Encephalopathy 
(BSE) (OJ L 105, 25.4.1990, p. 24)  
Restrictions on the dispatch of 
certain bovine tissues and 
organs from the UK 
  
90/261/EEC: Commission Decision of of 8 June 1990 
amending Decision 89/469/EEC concerning certain 
protection measures relating to bovine spongiform 
encephalopathy (BSE) in the United Kingdom and Decision 
90/200/EEC concerning additional requirements for some 
tissues and organs with respect to bovine spongiform 
encephalopathy (OJ L 146, 9.6.1990, p. 29) 
Amendment of Decisions 
89/469/EEC and 90/200/EEC - 
Guarantees on identification of 
animals and certification for 
beef dispatch 
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1991 
91/89/EEC: Commission Decision of 5 February 1991 
making financial provision for a project relating to the 
inactivation of the agents of scrapie and bovine spongiform 
encephalopathy (OJ L 49, 22.2.1991, p. 31) 
Financial provision for a 
project relating to the 
inactivation of the agents of 
scrapie and BSE 
1992 
92/290/EEC: Commission Decision of 14 May 1992 
concerning certain protection measures relating to bovine 
embryos in respect of bovine spongiform encephalopathy 
(BSE) in the United Kingdom (OJ L 49, 22.2.1991, p. 31) 
Restrictions on the dispatch of 
bovine embryos from the UK 
  
92/450/EEC: Commission Decision of 30 July 1992 
amending for the third time Council Directive 82/894/EEC on 
the notification of animal diseases within the Community and 
temporarily amending the frequency of notification for bovine 
spongiform encephalopathy(OJ L 248, 28.8.1992, p. 77) 
Compulsory notification of 
BSE (Repeals and replaces D 
90/134/EEC) 
1994 
94/381/EC: Commission Decision of 27 June 1994 
concerning certain protection measures with regard to bovine 
spongiform encephalopathy and the feeding of mammalian 
derived protein (OJ L 172, 7.7.1994, p. 23) 
Ban on the use of proteins 
derived from mammalian 
tissues for feeding ruminants 
  
94/382/EC: Commission Decision of 27 June 1994 on the 
approval of alternative heat treatment systems for processing 
animal waste of ruminant origin, with a view to the 
inactivation of spongiform encephalopathy (OJ L 172, 
7.7.1994, p. 25) 
Rendering systems for 
processing ruminant waste 
into MBM (inactivation of BSE 
agents) 
  
94/474/EC: Commission Decision of 27 July 1994 
concerning certain protection measures relating to bovine 
spongiform encephalopathy and repealing Decisions 
89/469/EEC and 90/200/EEC (OJ L 194, 29.7.1994, p. 96) 
Restrictions on the dispatch 
from the UK of live cattle and 
certain ruminant products - 
Destruction of specified bovine 
offal (Repeals D 89/469/EC 
and 90/200/EC) 
  
94/794/EC: Commission Decision of 14 December 1994 
concerning certain protection measures relating to bovine 
spongiform encephalopathy and repealing Decisions 
89/469/EEC and 90/200/EEC (OJ L 325, 17.12.1994, p. 60) 
Amendment of D 94/474/EC - 
Certification for beef dispatch 
1995 
95/29/EC: Commission Decision of 13 February 1995 
amending Decision 94/382/EC on the approval of alternative 
heat treatment systems for processing animal waste of 
ruminant origin, with a view to the inactivation of spongiform 
encephalopathy agents (OJ L 38, 18.2.1995, p. 17) 
Amendment of D 94/382/EC - 
Batch rendering systems 
  
95/60/EC: Commission Decision of 6 March 1995 
amending Decision 94/381/EC concerning certain protection 
measures with regard to bovine spongiform encephalopathy 
and the feeding of mammalian derived protein (OJ L 55, 
11.3.1995, p. 43) 
Amendment of D 94/381/EC - 
Derogation to the feed ban 
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95/287/EC: Commission Decision of 18 July 1995 
amending Decision 94/474/EEC concerning certain 
protection measures relating to bovine spongiform 
encephalopathy and repealing Decisions 89/469/EEC and 
90/200/EEC (OJ L 181, 1.8.1995, p. 40) 
Amendment of D 94/474/EC - 
Certification for beef dispatch 
1996 
96/239/EC: Commission Decision of 27 March 1996 on 
emergency measures to protect against bovine spongiform 
encephalopathy (OJ L 78, 28.3.1996, p. 47) 
Total ban on dispatch of live 
cattle and all cattle products 
from the UK (UK embargo) 
  
96/362/EC: Commission Decision of 11 June 1996 
amending Decision 96/239/EC on emergency measures to 
protect against bovine spongiform encephalopathy (OJ L 
139, 12.6.1996, p. 17) 
Amendment of D 96/239/EC - 
Conditional lifting of the ban 
for certain cattle products 
  
96/381/EC: Commission Decision of 20 June 1996 
approving the measures to be implemented as regards 
bovine spongiform encephalopathy in Portugal (OJ L 149, 
22.6.1996, p. 25) 
Eradication programme for 
BSE in Portugal 
  
96/385/EC: Commission Decision of 24 June 1996 
approving the plan for the control and eradication of bovine 
spongiform encephalopathy in the United Kingdom (OJ L 
151, 26.6.1996, p. 39) 
Eradication programme for 
BSE in the UK 
  
96/449/EC: Commission Decision of 18 July 1996 on the 
approval of alternative heat treatment systems for processing 
animal waste with a view to the inactivation of spongiform 
encephalopathy agents (OJ L 184, 24.7.1996, p. 43) 
Pressure cooking system for 
processing mammalian waste 
into MBM (inactivation of TSE 
agents) 
1997 
97/18/EC: Commission Decision of 16 December 1996 
approving the measures to be implemented as regards 
bovine spongiform encephalopathy in France (OJ L 6, 
10.1.1997, p. 43) 
Eradication programme for 
BSE in France 
  
97/312/EC: Commission Decision of 12 May 1997 
approving the measures to be implemented as regards 
bovine spongiform encephalopathy in Ireland (OJ L 133, 
24.5.1997, p. 38) 
Eradication programme for 
BSE in Ireland 
  
97/534/EC: Commission Decision of 30 July 1997 on the 
prohibition of the use of material presenting risks as regards 
transmissible spongiform encephalopathies (OJ L 216, 
8.8.1997, p. 95) 
Prohibition of the use of SRM 
(mainly brain, eyes and spinal 
cord) 
  
97/735/EC: Commission Decision of 21 October 1997 
concerning certain protection measures with regard to trade 
in certain types of mammalian animal waste ( OJ L 294, 
28.10.1997, p. 7) 
Restrictions on trade in MBM 
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Commission Directive 97/65/EC of 26 November 1997 
adapting, for the third time, to technical progress Council 
Directive 90/679/EEC on the protection of workers from risks 
related to exposure to biological agents at work (OJ L 335, 
6.12.1997, p. 17) 
Protection of workers from 
risks related to exposure to 
Spongiform Encephalopathy 
agents at work 
  
97/866/EC: Commission Decision of 16 December 1997 
amending Decision 97/534/EC on the prohibition of the use 
of material presenting risks as regards transmissible 
spongiform encephalopathies (OJ L 351, 23.12.1997, p. 69) 
Postponement to 1/4/1998 of 
the date of application of D 
97/534/EC (SRM) 
  
97/870/EC: Commission Decision of 16 December 1997 
amending Decision 96/385/EC approving the plan for the 
control and eradication of bovine spongiform encephalopathy 
in the United Kingdom (OJ L 353, 24.12.1997, p. 45) 
Amendment of D 96/385/EC - 
Clarification of the definition of 
high-risk cattle in the UK 
1998 
98/12/EC: Commission Decision of 15 December 1997 
amending for the fourth time Council Directive 82/894/EEC 
on the notification of animal diseases within the Community 
and temporarily amending the frequency of notification for 
bovine spongiform encephalopathy (OJ L 4, 8.1.1998, p. 63) 
Compulsory notification of 
BSE (Repeals and replaces D 
92/450/EEC) 
  
98/256/EC: Council Decision of 16 March 1998 concerning 
emergency measures to protect against bovine spongiform 
encephalopathy, amending Decision 94/474/EC and 
repealing Decision 96/239/EC (OJ L 113, 15.4.1998, p. 32) 
Amendment of the UK 
embargo - Reinforcement of 
controls and first steps 
towards lifting the ban under 
Export Certified Herds 
Scheme of Northern Ireland 
(Repeals D 96/239/EC) 
  
98/248/EC: Council Decision of 31 March 1998 amending 
Commission Decision 97/534/EC on the prohibition of the 
use of material presenting risks as regards transmissible 
spongiform encephalopathies (OJ L 102, 2.4.1998, p. 26) 
Postponement to 1/1/1999 of 
the date of application of D 
97/534/EC (SRM) 
  
98/272/EC: Commission Decision of 23 April 1998 on 
epidemio-surveillance for transmissible spongiform 
encephalopathies and amending Decision 94/474/EC (OJ L 
122, 24.4.1998, p. 59) 
Epidemio-surveillance for all 
animal TSEs 
  
98/351/EC: Commission Decision of 29 May 1998 setting 
the date on which dispatch from Northern Ireland of bovine 
products under the Export Certified Herds Scheme may 
commence by virtue of Article 6(5) of Council Decision 
98/256/EC (OJ L 157, 30.5.1998, p. 110) 
Date on which dispatch from 
Northern Ireland may 
commence (1/6/1998) 
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98/477/EC: Commission Recommendation of 22 July 1998 
concerning information necessary to support applications for 
the evaluation of the epidemiological status of countries with 
respect to transmissible spongiform encephalopathies (OJ L 
212 , 30/07/1998 p. 58) 
Information necessary to 
support applications for the 
evaluation of TSE status 
  
98/564/EC: Commission Decision of 7 October 1998 
amending Council Decision 98/256/EC as regards certain 
emergency measures to protect against bovine spongiform 
encephalopathy (OJ L 273, 9.10.1998, p. 37) 
Amendment of D 98/256/EC - 
Dispatch of BSE samples for 
scientific research 
  
98/653/EC: Commission Decision of 18 November 1998 
concerning emergency measures made necessary by the 
occurrence of bovine spongiform encephalopathy in Portugal 
(OJ L 311, 20.11.1998, p. 23) 
Total ban on dispatch of live 
cattle and all cattle products 
from Portugal (Portugal 
embargo) 
  
98/692/EC: Commission Decision of 25 November 1998 
amending Commission Decision 98/256/EC as regards 
certain emergency measures to protect against bovine 
spongiform encephalopathy (OJ L 328, 4.12.1998, p. 28) 
Amendment of the UK 
embargo - Principles of the 
second step towards lifting the 
ban under the Date-based 
Export Scheme applicable in 
the entire UK 
  
98/745/EC: Council Decision of 17 December 1998 
amending Commission Decision 97/534/EC on the 
prohibition of the use of material presenting risks as regards 
transmissible spongiform encephalopathies (OJ L 358, 
31.12.1998, p. 113) 
Postponement to 31/1/1999 of 
the date of application of D 
97/534/EC (SRM) 
1999 
1999/129/EC: Commission Decision of 29 January 1999 
amending for the second time Decision 94/381/EC 
concerning certain protection measures with regard to bovine 
spongiform encephalopathy and the feeding of mammalian 
derived protein (OJ L 41, 16.2.1999, p. 14) 
Amendment of D 94/381/EC - 
Hydrolysed proteins 
  
1999/514/EC: Commission Decision of 23 July 1999 
setting the date on which dispatch from the United Kingdom 
of bovine products under the date-based export scheme may 
commence by virtue of Article 6(5) of Council Decision 
98/256/EC (OJ L 195, 28.7.1999, p. 42) 
Date on which dispatch from 
the UK of certain bovine 
products may commence 
(1/8/1999) 
  
1999/517/EC: Commission Decision of 28 July 1999 
amending Decision 98/653/EC concerning emergency 
measures made necessary by the occurrence of bovine 
spongiform encephalopathy in Portugal (OJ L 197, 
29.7.1999, p. 45) 
Amendment of D 98/653/EC - 
Extension of the ban against 
Portugal 
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1999/534/EC: Council Decision of 19 July 1999 on 
measures applying to the processing of certain animal waste 
to protect against transmissible spongiform 
encephalopathies and amending Commission Decision 
97/735/EC (OJ L 204, 4.8.1999, p. 37) 
Conditions for the production 
of MBM and tallow (Repeals D 
96/449/EC) 
  
1999/713/EC: Commission Decision of 21 October 1999 
amending Decision 98/653/EC concerning emergency 
measures made necessary by the occurrence of bovine 
spongiform encephalopathy in Portugal (OJ L 281, 
4.11.1999, p. 90) 
Amendment of D 98/653/EC – 
Dispatch of MBM for 
incineration and fighting bulls 
  
1999/881/EC: Council Decision of 14 December 1999 
amending Commission Decision 97/534/EC on the 
prohibition of the use of material presenting risks as regards 
transmissible spongiform encephalopathies (OJ L 331, 
23.12.1999, p. 78) 
Postponement to 30 June 
2000 of the date of application 
of D 97/534/EC (SRM) 
2000 
2000/104/EC: Commission Decision f 31 January 2000 
amending Decision 98/653/EC concerning emergency 
measures made necessary by the occurrence of bovine 
spongiform encephalopathy in Portugal (OJ L 29, 4.2.2000, 
p. 36) 
Amendment of D 98/653/EC - 
Extension of the ban against 
Portugal 
  
2000/345/EC: Commission Decision of 22 May 2000 
setting the date on which dispatch from Portugal to Germany 
of certain products for the purpose of incineration may 
commence by virtue of Article 3(6) of Decision 98/653/EC 
(OJ L 121, 23.5.2000, p. 9) 
Starting date for the dispatch 
from Portugal of MBM for the 
purpose of incineration 
  
2000/371/EC: Commission Decision of 6 June 2000 setting 
the date on which dispatch of fighting bulls from Portugal to 
France may commence by virtue of Article 3(7) of Decision 
98/653/EC (OJ L 134, 7.6.2000, p. 34) 
Starting date for the dispatch 
from Portugal of fighting bulls 
to France 
  
2000/372/EC: Commission Decision of 6 June 2000 setting 
the date on which dispatch of fighting bulls from Portugal to 
Spain may commence by virtue of Article 3(7) of Decision 
98/653/EC (OJ L 134, 7.6.2000, p. 35) 
Starting date for the dispatch 
from Portugal of fighting bulls 
to Spain 
  
2000/374/EC: Commission Decision of 5 June 2000 
amending Decision 98/272/EC on epidemio-surveillance for 
transmissible spongiform encephalopathies (OJ L 135, 
8.6.2000, p. 27) 
Amendment of D 98/272/EC – 
Introduction of rapid post-
mortem test in monitoring for 
BSE 
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2000/418/EC: Commission Decision of 29 June 2000 
regulating the use of material presenting risks as regards 
transmissible spongiform encephalopathies and amending 
Decision 94/474/EC (OJ L 158, 30.6.2000, p. 76) 
Prohibition of the use of SRM 
(Repeals D 97/534/EC) 
  
2000/764/EC: Commission Decision of 29 November 2000 
on the testing of bovine animals for the presence of bovine 
spongiform encephalopathy and amending Decision 
98/272/EC on epidemio-surveillance for transmissible 
spongiform encephalopathies (OJ L 305, 6.12.2000, p. 35) 
Amendment of D 98/272/EC – 
Reinforcement of the 
surveillance 
  
2000/766/EC: Council Decision of 4 December 2000 
concerning certain protection measures with regard to 
transmissible spongiform encephalopathies and the feeding 
of animal protein (OJ L 306, 7.12.2000, p. 32) 
Temporary ban on use of 
MBM 
2001 
2001/2/EC: Commission Decision of 27 December 2000 
amending Decision 2000/418/EC regulating the use of 
material presenting risks as regards transmissible 
spongiform encephalopathies (OJ L 001 , 4.1.2001 p. 21)  
Amendment of D 2000/418/EC 
– Extension of the list of SRM 
(bovine intestines) 
  
2001/8/EC: Commission Decision of 29 December 2000 
amending Decision 2000/764/EC on the testing of bovine 
animals for the presence of bovine spongiform 
encephalopathy and updating Annex IV of Decision 
98/272/EC on epidemio-surveillance for transmissible 
spongiform encephalopathies (OJ L 2, 5.1.2001, p. 28) 
Amendment of D 2000/764/EC 
and update of D 98/272/EC 
  
2001/9/EC: Commission Decision of 29 December 2000 
concerning control measures required for the implementation 
of Council Decision 2000/766/EC concerning certain 
protection measures with regard to transmissible spongiform 
encephalopathies and the feeding of animal protein (OJ L 2, 
5.1.2001, p. 32) 
Conditions for feeding certain 
animal proteins 
  
2001/25/EC: Commission Decision of 27 December 2000 
prohibiting the use of certain animal by-products in animal 
feed (OJ L 6, 11.1.2001, p. 16) 
Prohibition of the use of dead 
animals in the production of 
animal feed 
  
2001/165/EC: Commission Decision of 27 February 2001 
amending as regards hydrolysed proteins Decision 
2001/9/EC concerning control measures required for the 
implementation of Council Decision 2000/766/EC concerning 
certain protection measures with regard to transmissible 
spongiform encephalopathies and the feeding of animal 
protein (OJ L 58, 28.2.2001, p. 43) 
Amendment of D 2001/9/EC – 
Hydrolysed proteins 
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2001/233/EC: Commission Decision of 14 March 2001 
amending Decision 2000/418/EC as regards mechanically 
recovered meat and bovine vertebral column (OJ L 84, 
23.3.2001, p. 59) 
Amendment of D 2000/418/EC 
– Extension of the list of SRM 
(vertebral column) 
  
2001/270/EC: Commission Decision of 29 March 2001 
amending Decision 2000/418/EC as regards imports from 
third countries (OJ L 94, 4.4.2001, p. 29) 
Amendment of D 2000/418/EC 
– Imports from third countries 
  
2001/376/EC: Commission Decision of 18 April 2001 
concerning measures made necessary by the occurrence of 
bovine spongiform encephalopathy in Portugal and 
implementing a date-based export scheme (OJ L 132, 
15.5.2001, p. 17) 
Principles for lifting the 
Portuguese ban under a Date-
based Export Scheme 
(Repeals D 98/653/EC) 
  
2001/384/EC: Commission Decision of 3 May 2001 
amending Decision 2000/418/EC as regards imports from 
Brazil and Singapore (OJ L 137, 19.5.2001, p. 29) 
Amendment of D 2000/418/EC 
– Extension of the list of 
derogating third countries 
  
Regulation (EC) 999/2001of the European Parliament and 
of the Council of 22 May 2001 laying down rules for the 
prevention, control and eradication of certain transmissible 
spongiform encephalopathies (OJ L 147, 31.5.2001, p. 1) 
Harmonized EU rules on 
prevention, control and 
eradication of certain TSE 
  
Commission Regulation (EC) No 1248/2001 of 22 June 
2001 amending Annexes III, X and XI to Regulation (EC) No 
999/2001 of the European Parliament and of the Council as 
regards epidemio-surveillance and testing of transmissible 
spongiform encephalopathies (OJ L 173, 27.6.2001, p. 12) 
Amendment of R 999/2001 – 
Surveillance and testing 
  
Commission Regulation (EC) No 1326/2001 of 29 June 
2001 laying down transitional measures to permit the 
changeover to the Regulation of the European Parliament 
and of the Council (EC) No 999/2001 laying down rules for 
the prevention, control and eradication of certain 
transmissible spongiform encephalopathies, and amending 
Annexes VII and XI to that Regulation (OJ L 177, 30.6.2001, 
p. 60) 
Amendment of R 999/2001 – 
Transitional measures 
  
2001/577/EC: Commission Decision of 25 July 2001 
setting the date on which dispatch from Portugal of bovine 
products under the Date-Based Export Scheme may 
commence by virtue of Article 22(2) of Decision 2001/376/EC 
(OJ L 203, 28.7.2001, p. 27) 
Date on which dispatch from 
Portugal of certain bovine 
products may commence 
(1/8/2001) 
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2002 
Commission Regulation (EC) No 270/2002 of 14 February 
2002 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards specified 
risk material and epidemio-surveillance for transmissible 
spongiform encephalopathies and amending Regulation (EC) 
No 1326/2001 as regards animal feeding and the placing on 
the market of ovine and caprine animals and products 
thereof (OJ L 45, 15.2.2002, p. 4) 
Amendments of R 999/2001 – 
SRM, surveillance, animal 
feeding and placing on the 
market of ovine and caprine 
animals and products thereof 
  
2002/248/EC: Commission Decision of 27 March 2002 
amending Council Decision 2000/766/EC and Commission 
Decision 2001/9/EC with regard to transmissible spongiform 
encephalopathies and the feeding of animal proteins (OJ L 
84, 28.3.2002, p. 71) 
Amending Council D 
2000/766/EC and Commission 
D 2001/9/EC with regard to 
the feeding of animal proteins 
  
2002/670/EC: Commission Decision of 20 August 2002 
amending Council Decision 98/256/EC concerning 
emergency measures to protect against bovine spongiform 
encephalopathy (OJ L 228, 24.8.2002, p. 22) 
Amendment off D 98/256/EC – 
Adaptation of some date-
based export scheme 
conditions 
  
Commission Regulation (EC) No 1494/2002 of 21 August 
2002 amending Annexes III, VII and XI to Regulation (EC) 
No 999/2001 of the European Parliament and the Council as 
regards monitoring of bovine spongiform encephalopathy, 
eradication of transmissible spongiform encephalopathy, 
removal of specified risk materials and rules for importation 
of live animals and products of animal origin (OJ L 225, 
22.8.2002, p. 3) 
Amendment of R 999/2001 – 
continuing of BSE testing in 
fallen stock. Deletion of the 
restrictions on trade of bovine 
embryos. Clarifications of 
some SRM rules 
  
2002/1003/EC: Commission Decision of 18 December 
2002 laying down minimum requirements for a survey of 
prion protein genotypes of sheep breeds (OJ L 349, 
24.12.2002, p. 105) 
Survey of prion protein 
genotypes of sheep breeds 
2003 
Commission Regulation (EC) No 260/2003 of 12 February 
2003 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards the 
eradication of transmissible spongiform encephalopathies in 
ovine and caprine animals and rules for the trade in live 
ovine and caprine animals and bovine embryos ( OJ L 37, 
13.2.2003, p. 7) 
Amendment of R 999/2001 – 
monitoring in ovine and 
caprine animals and rules for 
the trade in live ovine and 
caprine animals and bovine 
embryos 
  
2003/100/EC Commission Decision of 13 February 2003 
laying down minimum requirements for the establishment of 
breeding programmes for resistance to transmissible 
spongiform encephalopathies in sheep (OJ L 41, 14.2.2003, 
p. 41) 
Laying down minimum 
requirements for the 
establishment of breeding 
programmes for resistance to 
transmissible spongiform 
encephalopathies in sheep 
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Commission Regulation (EC) No 650/2003 of 10 April 
2003 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards the 
import of live ovine and caprine animals (OJ L 95, 11.4.2003, 
p. 15) 
Amendment of R 999/2001 – 
import conditions of live ovine 
and caprine animals 
  
Regulation (EC) No 1128/2003 of the European Parliament 
and of the Council of 16 June 2003 amending Regulation 
(EC) No 999/2001 as regards the extension of the period for 
transitional measures (OJ L 160, 28.6.2003, p. 1) 
Amendment of R 999/2001 – 
extension of the period for 
transitional measures 
  
Commission Regulation (EC) No 1053/2003 of 19 June 
2003 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards rapid 
tests (OJ L 152, 20.6.2003, p. 8) 
Amendment of R 999/2001 – 
extension of the list of rapid 
tests approved for TSE 
monitoring with two new tests 
– procedure for possible 
modification to the test or the 
test protocol 
  
Commission Regulation (EC) No 1139/2003 of 27 June 
2003 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards 
monitoring programmes and specified risk material (OJ L 
160, 28.6.2003, p. 22) 
Amendment of R 999/2001 – 
targeted testing should be 
carried out on animals 
destroyed following 
confirmation of TSE in ovine 
and caprine animals – 
amendments to the list of 
specified risk material in 
bovine, ovine and caprine 
animals – special provisions 
when harvesting the bovine 
tongue and head meat 
  
Commission Regulation (EC) No 1234/2003 of 10 July 
2003 amending Annexes I, IV and XI to Regulation (EC) No 
999/2001 of the European Parliament and of the Council and 
Regulation (EC) No 1326/2001 as regards transmissible 
spongiform encephalopathies and animal feeding (OJ L 173, 
11.7.2003, p. 6) 
Amendment of R 999/2001 – 
introducing the current 
provisions of the feed ban into 
Regulation (EC) No 999/2001 
without a fixed time schedule, 
thus ending the transitional 
nature of the feed ban 
  
Commission Regulation (EC) No 1809/2003 of 15 October 
2003 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards rules for 
importation of live bovine animals and products of bovine, 
ovine and caprine origin from Costa Rica and New Caledonia 
(OJ L 265, 16.10.2003, p. 10) 
Amendment of R 999/2001- 
deleting Costa Rica and 
including New Caledonia in 
the list of countries exempted 
from certain TSE-related trade 
conditions for live bovine 
animals and products of 
bovine, ovine and caprine 
origin 
  
 
68 
Year Legal text Contents 
  
Commission Regulation (EC) No 1874/2003 of 24 October 
2003 approving the national scrapie control programmes of 
certain Member States, and defining additional guarantees, 
and granting derogations concerning breeding programmes 
for TSE resistance in sheep pursuant to Decision 
2003/100/EC (OJ L 275, 25.10.2003, p. 12) 
Derogations for certain 
Member States concerning 
breeding programmes for TSE 
resistance in sheep 
  
Commission Regulation (EC) No 1915/2003 of 30 October 
2003 amending Annexes VII, VIII and IX to Regulation (EC) 
No 999/2001 of the European Parliament and of the Council 
as regards the trade and import of ovine and caprine animals 
and the measures following the confirmation of transmissible 
spongiform encephalopathies in bovine, ovine and caprine 
animals (OJ L 283, 31.10.2003, p. 29) 
Amendment of R 999/2001- 
modification of the measures 
following the confirmation of 
transmissible spongiform 
encephalopathies in bovine, 
ovine and caprine animals – 
amendments to the trade and 
imports rules of ovine and 
caprine animals 
  
Commission Regulation (EC) No 2245/2003 of 19 
December 2003 amending Annex III to Regulation (EC) No 
999/2001 of the European Parliament and of the Council as 
regards monitoring of transmissible spongiform 
encephalopathies in ovine and caprine animals (OJ L 333, 
20.12.2003, p. 28) 
Amendment of R 999/2001 – 
modification to the ovine and 
caprine surveillance 
programme 
2004 
Commission Regulation (EC) No 836/2004 of 28 April 
2004 laying down the transitional measures to be applied by 
Cyprus with regard to scrapie (OJ L 127, 29.4.2004, p. 48) 
Laying down the transitional 
measures to be applied by 
Cyprus with regard to Scrapie 
  
Commission Regulation (EU) No 876/2004 of 29 April 
2004 amending Annex VIII to Regulation (EC) No 999/2001 
of the European Parliament and of the Council as regards 
trade in ovine and caprine animals for breeding (OJ L 162, 
30.4.2004, p. 52) 
Amendment of R 999/2001 – 
trade in bovine and caprine 
animals for breeding 
  
Commission Regulation (EU) No 1471/2004 of 18 August 
2004 amending Annex XI to Regulation (EC) No 999/2001 of 
the European Parliament and of the Council as regards the 
import of cervid products from Canada and the United States 
(OJ L 271, 19.8.2004, p. 24) 
Amendment of R 999/2001 – 
introducing requirements for 
the import of cervid products 
from Canada and the United 
States 
  
Commission Regulation (EU) No 1472/2004 of 18 August 
2004 amending Regulation (EC) No 1874/2003 approving 
the national scrapie control programmes of certain Member 
States, and defining additional guarantees, and granting 
derogations concerning breeding programmes for TSE 
resistance in sheep pursuant to Decision 2003/100/EC (OJ L 
271, 19.8.2004, p. 26) 
Amendment of R 1874/2003 - 
Derogations for certain 
Member States concerning 
breeding programmes for TSE 
resistance in sheep 
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Year Legal text Contents 
  
Commission Regulation (EU) No 1492/2004 of 23 August 
2004 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards 
eradication measures for transmissible spongiform 
encephalopathies in bovine, ovine and caprine animals, the 
trade and importation of semen and embryos of ovine and 
caprine animals and specified risk material (OJ L 274, 
24.8.2004, p. 3) 
Amendment of R 999/2001 – 
modification of eradication 
measures for bovine, ovine 
and caprine animals, trade 
and import conditions for 
semen and embryos of ovine 
and caprine animals and the 
list of specified risk materials 
  
2004/653/EC: Commission Decision of 16 September 2004 
amending Commission Decision 2001/376/EC as regards the 
dispatch of meat-and-bone meal of mammalian origin and 
related products from Portugal (OJ L 298, 23.9.2004, p. 25) 
Amendment of Commission 
Decision 2001/376/EC as 
regards the dispatch of meat-
and-bone meal of mammalian 
origin and related products 
from Portugal 
  
Commission Regulation (EU) 1993/2004 of 19 November 
2004 amending Regulation (EC) 999/2001 of the European 
Parliament and of the Council as regards Portugal (OJ L 344, 
20.11.2004, p. 12) 
Lifting of the embargo on 
Portugal – Amendment of R 
999/2001 as regards SRM and 
repeal of Commission 
Decision 2001/376/EC and 
related measures 
2005 
Commission Regulation (EC) No 36/2005 of 12 January 
2005 amending Annexes III and X to Regulation (EC) No 
999/2001 of the European Parliament and of the Council as 
regards epidemio-surveillance for transmissible spongiform 
encephalopathies in bovine, ovine and caprine (J L 10, 
13.1.2005, p. 9) 
Amendment of R 999/2001 – 
Systematic discriminatory 
tests (differentiation BSE-
scrapie) for all confirmed TSE 
cases in small ruminants 
  
Commission Regulation (EC) 214/2005 of 9 February 2005 
amending Annex III to Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards 
monitoring of transmissible spongiform encephalopathies in 
caprine animals (OJ L 37, 10.2.2005, p. 9) 
Amendment of R 999/2001 – 
Increased TSE monitoring in 
goats 
  
Commission Regulation (EU) No 260/2005 of 16 February 
2005 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards rapid 
tests (OJ L 46, 17.2.2005, p. 31) 
Amendment of R 999/2001 - 
Approval of new rapid tests 
  
Regulation (EC) No 932/2005 of the European Parliament 
and of the Council of 8 June 2005 amending Regulation (EC) 
No 999/2001 laying down rules for the prevention, control 
and eradication of certain transmissible spongiform 
encephalopathies as regards the extension of the period for 
transitional measures (OJ L 163, 23.6.2005, p. 1) 
Amendment of R 999/2001 – 
Extension of the period for 
transitional measures 
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Year Legal text Contents 
  
2005/598/EC: Commission Decision of 2 August 2005 
prohibiting the placing on the market of products derived 
from bovine animals born or reared within the United 
Kingdom before 1 August 1996 for any purpose and 
exempting such animals from certain control and eradication 
measures laid down in Regulation (EC) No 999/2001 (OJ L 
204, 5.8.2005, p. 22) 
Prohibiting the placing on the 
market of products derived 
from bovine animals born or 
reared in the UK before 1 
August 1996 
  
Commission Regulation (EC) No 1292/2005 of 5 August 
2005 amending Annex IV to Regulation (EC) No 999/2001 of 
the European Parliament and of the Council as regards 
animal nutrition (OJ L 205, 6.8.2005, p. 3) 
Amendment of R 999/2001 as 
regards animal nutrition 
  
Commission Regulation (EC) No 1974/2005 of 2 
December 2005 amending Annexes X and XI to Regulation 
(EC) No 999/2001 of the European Parliament and of the 
Council as regards national reference laboratories and 
specified risk material (OJ L 317, 3.12.2005, p. 4) 
Amendment of R 999/2001 as 
regards national reference 
laboratories and Specified 
Risk Materials – modification 
of the age limit for vertebral 
column in bovines 
2006 
Commission Regulation (EC) No 253/2006 of 14 February 
2006 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards rapid 
tests and measures for the eradication of TSEs in ovine and 
caprine animals (OJ L 44, 15.2.2006, p. 9) 
Amendment of R 999/2001 as 
regards rapid tests and TSE 
eradication measures on small 
ruminants 
  
Commission Regulation (EC) No 339/2006 of 24 February 
2006 amending Annex XI to Regulation (EC) No 999/2001 of 
the European Parliament and of the Council as regards the 
rules for importation of live bovine animals and products of 
bovine, ovine and caprine origin (OJ L 55, 25.2.2006, p. 5) 
Amendment of R 999/2001- 
deleting Brazil, Chile, El 
Salvador, Nicaragua, Namibia, 
Botswana and Swaziland from 
the list of countries exempted 
from certain TSE-related trade 
conditions for live bovine 
animals and products of 
bovine, ovine and caprine 
origin 
  
Commission Regulation (EC) No 546/2006 of 31 March 
2006 implementing Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards national 
scrapie control programmes and additional guarantees and 
derogating from certain requirements of Decision 
2003/100/EC and repealing Regulation (EC) No 1874/2003 
(OJ L 94, 1.4.2006, p. 28) 
Implementing R 999/2001 as 
regards national scrapie 
control programmes and 
additional guarantees and 
derogating from certain 
requirements as regards 
breeding programmes in 
certain Member States 
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Year Legal text Contents 
  
Commission Regulation (EC) No 657/2006 of 10 April 
2006 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards the 
United Kingdom and repealing Council Decision 98/256/EC 
and Decisions 98/351/EC and 1999/514/EC (OJ L 116, 
29.4.2006, p. 9) 
Lifting of the embargo on the 
United Kingdom – Amendment 
of R 999/2001 as regards 
SRM, BSE monitoring and 
repeal of Commission 
Decision 98/256/EC and 
related measures 
  
Commission Regulation (EC) No 688/2006 of 4 May 2006 
amending Annexes III and XI to Regulation (EC) No 
999/2001 of the European Parliament and of the Council as 
regards the monitoring of transmissible spongiform 
encephalopathies and specified risk material of bovine 
animals in Sweden (OJ L 120, 5.5.2006, p. 10) 
Amendment of R 999/2001 as 
regards BSE monitoring in 
Sweden 
  
Commission Regulation (EU) No 1041/2006 of 7 July 2006 
amending Annex III to Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards 
monitoring of transmissible spongiform encephalopathies in 
ovine animals (OJ L 187, 8.7.2006, p. 10) 
Amendment of R 999/2001 as 
regards TSE monitoring in 
sheep. Increased number of 
tests 
  
Regulation (EC) No 1923/2006 of the European Parliament 
and of the Council of 18 December 2006 amending 
Regulation (EC) No 999/2001 laying down rules for the 
prevention, control and eradication of certain transmissible 
spongiform encephalopathies (OJ L 404, 30.12.2006, p. 1) 
Amendment of R 999/2001 as 
regards categorisation of 
countries, specified risk 
materials, TSE surveillance, 
Import conditions 
2007 
2007/182/EC: Commission Decision of 19 March 2007 on 
a survey for chronic wasting disease in cervids (OJ L 84, 
24.3.2007, p. 37) 
Laying down rules for a survey 
for Chronic wasting disease in 
cervids 
  
2007/315/EC: Commission Decision of 30 April 2007 laying 
down specific measures to be applied by Cyprus with regard 
to scrapie (OJ L 118, 8.5.2007, p. 23) 
Specific measures for Cyprus 
regarding scrapie 
  
Commission Regulation (EC) No 722/2007 of 25 June 
2007 amending Annexes II, V, VI, VIII, IX and XI to 
Regulation (EC) No 999/2001 of the European Parliament 
and of the Council laying down rules for the prevention, 
control and eradication of certain transmissible spongiform 
encephalopathies (OJ L 164, 26.6.2007, p. 7) 
Amendment of R 999/2001. 
End of transitional measures 
from 1 July 2007 
  
Commission Regulation (EC) No 727/2007 of 26 June 
2007 amending Annexes I, III, VII and X to Regulation (EC) 
No 999/2001 of the European Parliament and of the Council 
laying down rules for the prevention, control and eradication 
of certain transmissible spongiform encephalopathies (OJ L 
165, 27.6.2007, p. 8) 
Amendment of R 999/2001. 
modification of eradication 
measures for ovine and 
caprine animals and 
monitoring in ovine and 
caprine animals 
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Year Legal text Contents 
  
2007/453/EC: Commission Decision of 29 June 2007 
establishing the BSE status of Member States or third 
countries or regions thereof according to their BSE risk (OJ L 
172, 30.6.2007, p. 84) 
Establishing the BSE status of 
Member States and certain 
third countries 
  
2007/667/EC: Commission Decision of 15 October 2007 
authorising the use of at risk bovine animals until the end of 
their productive lives in Germany following official 
confirmation of the presence of BSE (OJ L 271, 16.10.2007, 
p. 16) 
BSE cohort culling in Germany 
  
Commission Regulation (EC) No 1275/2007 of 29 October 
2007 amending Annex IX to Regulation (EC) No 999/2001 of 
the European Parliament and of the Council laying down 
rules for the prevention, control and eradication of certain 
transmissible spongiform encephalopathies (OJ L 284, 
30.10.2007, p. 8) 
Amendment of R 999/2001. 
Import conditions for products 
of animal origin from bovine, 
ovine and caprine animals 
  
Commission Regulation (EC) No 1428/2007 of 4 
December 2007 amending Annex VII to Regulation (EC) No 
999/2001 of the European Parliament and of the Council 
laying down rules for the prevention, control and eradication 
of certain transmissible spongiform encephalopathies (OJ L 
317, 5.12.2007, p. 61) 
Amendment of R 999/2001. 
Derogation: possibility to delay 
the destruction of animals in 
TSE affected flocks for 5 
breeding years 
2008 
Commission Regulation (EC) No 21/2008 of 11 January 
2008 amending Annex X to Regulation (EC) No 999/2001 of 
the European Parliament and of the Council as regards the 
lists of rapid tests (OJ L 9, 12.1.2008, p. 3) 
Amendment of R 999/2001. 
List of rapid tests 
  
Commission Regulation (EC) No 315/2008 of 4 April 2008 
amending Annex X to Regulation (EC) No 999/2001 of the 
European Parliament and of the Council as regards the lists 
of rapid tests (OJ L 94, 5.4.2008, p. 3) 
Amendment of R 999/2001. 
List of rapid tests 
  
Commission Regulation (EC) No 357/2008 of 22 April 
2008 amending Annex V to Regulation (EC) No 999/2001 of 
the European Parliament and of the Council laying down 
rules for the prevention, control and eradication of certain 
transmissible spongiform encephalopathies (OJ L 111, 
23.4.2008, p. 3) 
Amendment of R 999/2001. 
Modification of the age limit for 
vertebral column in bovines 
  
Commission Regulation (EC) No 571/2008 of 19 June 
2008 amending Annex III to Regulation (EC) No 999/2001 of 
the European Parliament and of the Council as regards the 
criteria for revision of the annual monitoring programmes 
concerning BSE (OJ L 161, 20.6.2008, p. 4) 
Amendment of R 999/2001. 
Criteria for the revision of 
annual BSE monitoring 
programmes 
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Year Legal text Contents 
  
Commission Regulation (EC) No 746/2008 of 17 June 
2008 amending Annex VII to Regulation (EC) No 999/2001 
of the European Parliament and of the Council laying down 
rules for the prevention, control and eradication of certain 
transmissible spongiform encephalopathies (OJ L 202, 
31.7.2008, p. 11) 
Amendment of R 999/2001. 
modification of eradication 
measures for ovine and 
caprine animals 
: 
2008/661/EC: Commission Decision of 1 August 2008 
amending Decision 2007/182/EC on a survey for chronic 
wasting disease in cervids (OJ L 215, 12.8.2008, p. 8)  
Extending the survey for 
Chronic wasting disease in 
cervids 
  
Commission Regulation (EC) No 956/2008 of 29 
September 2008 amending Annex IV to Regulation (EC) No 
999/2001 of the European Parliament and of the Council 
laying down rules for the prevention, control and eradication 
of certain transmissible spongiform encephalopathies (OJ L 
260, 30.9.2008, p. 8) 
Amendment of R 999/2001. 
Authorisation for the use of 
fishmeal in milk replacers 
intended for feeding to young 
animals of ruminant species 
  
Commission Decision (EC) 2008/829 of 30 October 2008 
amending the Annex to Decision 2007/453/EC establishing 
the BSE status of Member States or third countries or 
regions thereof according to their BSE risk (OJ L 294, 
1.11.2008, p. 14) 
Member States and third 
countries or regions thereof 
are classified into three risk 
categories as regards BSE 
(negligible risk, controlled risk 
and undetermined risk) 
according to OIE standards 
  
Commission Decision (EC) 2008/908 of 28 November 
2008 authorising certain Member States to revise their 
annual BSE monitoring programme (OJ L 327, 5.12.2008, p. 
24)  
Certain Member States may 
revise their annual BSE 
monitoring programme 
2009 
Commission Regulation (EC) No 220/2009 of 11 March 
2009 amending Regulation (EC) No 999/2001 of the 
European Parliament and of the Council laying down rules 
for the prevention, control and eradication of certain 
transmissible spongiform encephalopathies, as regards the 
implementing powers conferred on the Commission (OJ L 
87, 31.3.2009, p. 155) 
Amendment of R 999/2001. 
Modification of the 
implementing powers 
conferred on the Commission 
  
Commission Regulation (EC) No 103/2009 of 3 February 
2009 amending Annexes VII and IX to Regulation (EC) No 
999/2001 of the European Parliament and of the Council 
laying down rules for the prevention, control and eradication 
of certain transmissible spongiform encephalopathies (OJ L 
34, 4.2.2009, p. 11) 
Amendment of R 999/2001. 
Modification of eradication 
measures for ovine and 
caprine animals 
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Commission Regulation (EC) No 162/2009 of 26 February 
2009 amending Annexes III and X to Regulation (EC) No 
999/2001 of the European Parliament and of the Council 
laying down rules for the prevention, control and eradication 
of certain transmissible spongiform encephalopathies (OJ L 
55, 27.2.2009, p. 11) 
Amendment of R 999/2001. 
Modification of certain 
approved laboratory methods 
for the diagnostic of TSEs 
  
Commission Regulation (EC) No 163/2009 of 26 February 
2009 amending Annex IV to Regulation (EC) No 999/2001 of 
the European Parliament and of the Council laying down 
rules for the prevention, control and eradication of certain 
transmissible spongiform encephalopathies (OJ L 55, 
27.2.2009, p. 17) 
Amendment of R 999/2001. 
Modification of certain feed 
ban provisions 
 
In 2005, in order to clarify all previous legislation on TSEs, the European 
Commission presented "The TSE Roadmap” (The TSE Roadmap, 2005) and 
in 2010 the Commission communicated to Parliament its views and intentions 
for the future in "The TSE Road Map 2 - A strategy Paper on Transmissible 
Spongiform Encephalopathies for 2010 - 2015”. In the Communication, the 
European Commission outlines its vision on further changes to the TSE 
eradication measures and the TSE surveillance regime. 
On 6 July 2011, the European Parliament (EP) adopted a resolution on the 
implementation and outlook for EU legislation on TSEs and on related feed 
and food controls. 
The resolution states that despite the fall in BSE cases in the EU, surveillance 
must remain vigilant and any change to BSE safety rules must maintain high 
animal and public health standards. However, the ban on feeding animal 
protein to non-ruminants, such as pigs, could gradually be lifted if more 
safeguards are implemented. The resolution indicates that the European 
Commission is shortly expected to review changes to current EU laws, which 
  
 
75 
could include new rules on removing specific risk materials from animal feed, 
a gradual relaxation of the animal protein feed ban, changes to cohort culling 
policy and a higher age limit for BSE testing (EP Resolution, 6 July 2011). 
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10 - EXPERIMENTAL STUDIES 
The Microbiology and Immunology Section of the Department of Veterinary 
Pathology, Hygiene and Public Health of the School of Veterinary Medicine at 
the University of Milan has been involved for long in the study of TSEs 
(Pollera et al., 2003; Poli et al., 2004; Magri et al., 2005; Bareggi et al., 2009; 
Bondiolotti et al., 2010). Just in this context and field I carried out my doctoral 
studies, being involved in three experimental projects aimed to clarify different 
aspects of prion diseases. In all of them we used wild-type mouse bioassays, 
which are the gold standard for assessing the biological properties of prions 
(Bruce et al., 2002; Beck et al., 2010 b). 
In the first study our goal was to assess the therapeutic and/or preventive 
activity on TSEs of the chronic administration of a new γ-secretase modulator. 
The second research investigated the ability to identify BSE in presence of 
scrapie. The third project was aimed to study the effects induced by chronic 
administration of lipid enriched/depleted specific diets on the pathogenesis of 
prion diseases. 
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11 - THERAPEUTIC EFFECT OF CHF5074, A 
NEW γ-SECRETASE MODULATOR, IN A MOUSE 
MODEL OF SCRAPIE 
The laboratory analysis of this experimental study were performed at the 
Italian Reference Laboratory for TSEs (CEA), Istituto Zooprofilattico Sperimentale del 
Piemonte, Liguria e Valle d’Aosta, Turin, Italy, during my training period there 
(November 1st, 2009 – December 6th, 2009). 
 
The similarities between TSEs and AD suggest that drugs effective for the 
treatment of AD can be successfully used for the treatment of TSEs too. 
Some non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to 
allosterically modulate the activity of γ-secretase. 1-(3',4'-Dichloro-2-
fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074) (Figure 10) 
is a new NSAID γ-secretase modulator, that is proposed as a potential 
therapeutic agent in AD, because of its promising effects and its lack of 
toxicity.  
Figure 10. Structural formula of CHF5074 (Imbimbo et al., 2007 a). 
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The chronic oral administration of CHF5074 in two different transgenic murine 
models of AD reduces the deposition of Aβ in the brain, both in terms of area 
occupied by plaques and number of plaques, and attenuates the spatial 
memory impairment (Imbimbo et al., 2007 a, b; Imbimbo et al., 2009; Imbimbo 
et al., 2010 a). Moreover it seems to have a good bioavailability, since it is 
orally well absorbed (50 %) and it is slowly eliminate from the blood (half-life
 
= 
20 h) (Peretto et al., 2005). In contrast with other NSAIDs, CHF5074 has not 
toxic effects, because it is endowed with selective Aβ42-lowering activity but 
devoid of COX and NOTCH inhibitory activity, and so it is suitable for chronic 
use (Imbimbo et al., 2007 b; Imbimbo et al., 2009). 
The aim of the present study is to assess the therapeutic and/or preventive 
activity of CHF5074 on murine model experimentally infected with the 
causative agent of prion diseases. 
11.1 – MATERIALS AND METHODS 
11.1.1 - Animals and Treatments 
Ninety-one CD1 female mice aged 3-4 weeks and initially weighing 10-12 g 
were under survey. Outbred CD1 mouse strain was used to mimic the 
conditions of a previous study with a γ-secretase inhibitor (Spilman et al., 
2008). Mice were maintained in a controlled environment (22 ± 1 °C, 55 ± 5% 
relative humidity, 12-h light/dark cycles) and fed ad libitum.  
Mice were neither be handled nor disturbed for a week, to allow them to settle 
in. 
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Then animals were randomly divided into two groups according to the route of 
infection (intracerebrally, i.c., or intraperitoneally, i.p.) with the mouse-adapted 
Rocky Mountains Laboratory (RML) scrapie. A 10% (weight/volume) 
homogenate of RML-infected CD1 brain was diluted in sterile saline to a final 
concentration of 1%, and 25 µl or 50 µl of the suspension were injected i.c. or 
i.p., respectively. 
The i.c. inoculation occurred always on the right side of the skull, at the 
thalamic level. After analgesia with lidocaine 2 %, each animal was lying on 
his left side and the skin of his skull was stretched: the landmark for the 
injection was located 3 mm dorsal to the middle of an imaginary line drawn 
between the lateral canthus of the eye and the ear. The insulin syringe used 
had a cylinder spacer on its needle, which ensured the constant depth of the 
injection, performed perpendicularly to the skull.  
The i.p. inoculation was made into the caudal left (to avoid the cecum on the 
right) abdominal quadrant. Each mouse was restrained manually and held 
with the head and body tilted downward. The injection was performed with an 
insulin syringe: the tip of the needle was inserted through the skin and just 
past the abdominal wall, avoiding to perforate abdominal organs. 
The day of scrapie inoculation was considered as Day 1 of the study. Animals 
in the infected groups (i.c. or i.p.) were then split into two subgroups, each 
consisting of 15 CHF5074-treated or vehicle-treated mice (i.c. infected 
CHF5074-treated, i.c. infected vehicle-treated; i.p. infected CHF5074-treated; 
i.p. infected vehicle-treated). Similarly, uninfected animals were divided into 
two subgroups of 8 animals each, then CHF5074-treated and inoculated i.c. 
or i.p. respectively with the same volume of a 1% brain homogenate from 
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uninfected CD1 mice (i.c. uninfected CHF5074-treated; i.p. uninfected 
CHF5074-treated). Furthermore, a negative group was created, uninfected 
and vehicle-treated. CHF5074-treated animals received an oral diet 
medicated with CHF5074 (375 ppm, corresponding to approximately 60 
mg/kg/day) while vehicle-treated animals were given a standard diet. 
CHF5074 was manufactured by Minakem (Beuvry-la-Forêt, France) and 
CHF5074-medicated diet (4RF21 certificate – PF1610 – mice and rats) by 
Mucedola (Settimo Milanese, Italy). CHF5074-medicated and standard diets 
were started 14 days before scrapie strain inoculation (Table 6).  
Table 6. Mice were randomly divided into groups depending on the route of  inoculum and on 
the type of treatment. 
 
Mice were observed daily to monitor for onset and development of 
neurological signs, such as kyphotic posture, ataxia, proprioceptive deficits, 
lethargy and frozen posture. All mice were euthanized with CO2 when severe 
symptoms were apparent as previously described (Thackry et al., 2002; 
Meeker et al., 2005). 
At necropsy brains (cerebral hemispheres, brain stem and cerebellum) were 
removed. Each brain was then divided longitudinally; one part was fixed in 
Groups Treatment
i.c. Infected vehicle-treated intracerebral standard diet 15
i.c. Infected CHF5074-treated intracerebral CHF5074 15
i.p. Infected vehicle-treated intraperitoneal standard diet 15
i.p. Infected CHF5074-treated intraperitoneal CHF5074 15
i.c. Uninfected CHF5074-treated intracerebral CHF5074 8
i.p. Uninfected CHF5074-treated intraperitoneal CHF5074 8
Uninfected vehicle-treated / standard diet 15
Route of 
inoculum
Number of 
animals
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10% formalin for histopathological and immunohistochemical analysis, and 
the other was stored at -20 °C for Western Blot ana lysis.  
11.1.2 - Western blot analysis 
Ten percent (w/v) homogenates of each frozen brain were prepared in lysis 
buffer (10% N-lauroylsarcosine diluted in Tris Buffer Saline -TBS- pH 7.4). 
After incubation for 20-30 minutes at room temperature, they were clarified by 
centrifugation at 22000x g for 20 minutes at 10 °C (Ultracentrifuge Optima 
TLX, Rotor TLA 55, Beckman Coulter, Fullerton, CA). A rate of 1 mL was 
removed from each supernatant and digested with pK (40 µg/mL; Product N° 
FS-M-112; Fisher Molecular Biology, Trevose, USA) for 1 hour at 37 °C with 
continuous shaking. After digestion, 10 µL of the proteinase K inhibitor 
phenylmethyl sulfonyl fluoride (PMSF 100 mM; Product N° A0999; Applichem, 
Germany) were added. The samples were then centrifuged at 215000x g for 1 
hour at 10 °C (Ultracentrifuge Optima TLX, Rotor TL A 110, Beckman Coulter, 
Fullerton, CA). The pellets obtained were dissolved in 50 µL of Laemmli 
buffer. After boiling for 5-10 minutes at 99 °C, 10  µL of each extract (10 mg of 
tissue) were separated by sodium dodecyl-sulfate polyacrylamide gel 
electrophoresis on a 12 % handmade minigel (acrylamide to bisacrylamide 
ratio of 37.5:1) and then transferred onto PVDF membranes (Product N° 
IPVH20200; Immobilion P, Millipore, Billerica, MA). Blots were blocked with 
TBS-BSA 5% and incubated at 4 °C overnight with the  monoclonal antibody 
SAF 70 (0,5 µg/ml; Product N° A023206; Spi Bio, Cayman Chemical,  Ann 
Arbor, MI), recognising human PrP residues 142-160. The immunodetection 
was carried out with an alkaline phosphatase-conjugated goat anti-mouse IgG 
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(Product N° 12000-09; Prionics AG, Switzerland) rev ealed by a 
chemiluminescent substrate (Product N° 170-5012; Im munoStar, Bio-Rad 
Laboratories, Hercules, CA) and then visualised onto Hyperfilm ECL (Product 
N° 28906837; GE-Healthcare, St. Giles, UK) or by a UVI Prochemi (Uvitec, 
Cambridge, UK) analysis system. PrPSc signals of each sample were 
quantified using UVI Bandmap software (Uvitec, Cambridge, UK), comparing 
them with the PrPSc signals of a classical scrapie sample, used as reference. 
11.1.3 - Histopathological and immunohistochemical 
analysis 
Following fixation, brains were coronally cut into five sections (medulla, pons 
and cerebellum, mid-brain, diencephalon, telencephalon) (Fraser et al., 1968). 
These samples were processed (Table 7) and embedded in paraffin wax 
according to standard histopathological procedures.  
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Table 7. Mouse processing procedure. 
 
The 3 µm-thick sections obtained from each hemisphere were placed on 
slides with positive electrostatic charge and left for 24 hours at 37 °C. An 
hematoxylin-eosin staining was performed for each brain section (Table 8).  
Table 8. Haematoxylin-eosin staining procedure. 
 
Step Reagent Time
1 95 % Alcohol 2 h
2 95 % Alcohol 2 h
3 95 % Alcohol 2 h
4 95 % Alcohol 3 h
5 Absolute Alcohol 30 min 
6 Absolute Alcohol 30 min 
7 Absolute Alcohol + Xylene (1:1) 30 min
8 Xylene 1 h 30 min
9 Xylene 1 h 30 min
10 Xylene + Wax (4:1) 30 min
11 Wax 1 h
12 Wax 1 h
Step Reagent Time
1 Xylene 3 min
2 Absolute Alcohol 3 min
3 Mayer's Haematoxylin 17 min
4 Tap water 5 min
5 0,1 & Acid Alcohol 1 min
6 Tap water 5 min
7 1,5 % Lithium Carbonate 30 sec
8 Purified Water 2 min
9 Eosin 31 sec
10 Tap water 5 min
11 Absolute Alcohol 1 min
12 Absolute Alcohol 3 min
13 Xylene 3 min
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Slides for immunohistochemical analysis were dewaxed and rehydrated by 
routine methods and then immersed in 98% formic acid for 15 minutes. After 
washing in water, the sections were autoclaved for 30 minutes at 121 °C in 
citrate buffer (pH 6.1) to unmask antigenic sites. Endogenous peroxidase 
activity was blocked in 3% hydrogen peroxide diluted in methanol for 20 
minutes at room temperature and samples were left overnight in distilled 
water at 2-8 °C. To block non-specific tissue antig ens, the sections were 
incubated with 2% horse blocking serum (pH 7.4) for 20 minutes at room 
temperature and then incubated for 1 hour at room temperature with the 
mouse monoclonal antibody ICSM 35 diluted 1:1000 (Product N° 0130-03501, 
D-Gen Ltd. London UK). ICSM 35 monoclonal antibodies have been shown to 
efficiently immunoprecipitate native PrPSc and recognised epitopes between 
residues 93-102 (Khalili-Shirazi et al., 2005). After rinsing in TBST, a 
biotinylated goat anti-mouse secondary antibody (1:200 dilution, Vectastain 
ABC kit PK-4002, Vector Laboratories) was applied to the tissue sections for 
30 minutes at room temperature, followed by the avidin-biotin-peroxidase 
complex (Vectastain ABC kit PK-4002, Vector Laboratories), according to the 
manufacturer’s protocol. After rinsing in TBST, PrPSc immunoreactivity was 
visualised using 3,3’-diaminobenzidine (Dako Liquid DAB + Substrate 
Chromogen System Cod. K3468, Dako) as a chromogen, blocked with 
distilled water. The sections were then counterstained with Mayer’s 
haematoxylin (Table 9). 
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Table 9. Counterstain in Mayer's haematoxylin procedure. 
 
Spongiosis and PrPSc deposition in different encephalic areas (medulla, 
cerebellum, mid-brain, hypothalamus, thalamus, hippocampus, para terminal 
body, frontal cortex and parietal cortex) were evaluated by light microscopy 
and an intensity grade was assigned to vacuolation and to different patterns 
detected: absent (0), slight (1), moderate (2), marked (3), very marked (4). 
11.1.4 - Statistical analysis 
The survival analysis was performed using the Log-Rank test. To evaluate the 
differences in the PrPSc among the groups, the results of quantification 
performed by Western blot analysis were analysed by ANOVA, after checking 
the assumption of normality and homogeneity of variances. Data obtained by 
histological and immunohistochemical analysis were analysed by Student t 
test for unpaired data with equal variances. 
Step Reagent Time
1 Tap Water 5 min
2 Mayer's Haematoxylin 1 min 10 sec
3 Tap Water 7 min
4 Absolute Alcohol 3 min
5 Absolute Alcohol 3 min
6 Absolute Alcohol 3 min
7 Xylene 3 min
8 Xylene 3 min
9 Xylene 3 min
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11.2 - RESULTS 
11.2.1 - Survival of the animals 
Uninfected treated and control animals did not show any clinical signs of 
disease. Early clinical signs of prion disease induced by RML strain of scrapie 
set out in control mice appearing at about Day 130 in the i.c.-infected animals 
and at Day 180 in i.p.-infected animals. Mice initially displayed ruffled coats, 
assumed kyphotic posture and a tendency to display a straight tail. These 
early signs of prion disease were followed by ragged or wobbly gait, ataxia 
and proprioceptive deficits, as evidenced by clasped feet when raised by tail. 
Then, they became extremely listless, lethargic and cachectic and appeared 
to adopt a frozen posture. All mice of the infected groups, except for two 
animals in the i.p.-infected CHF5074-treated group, reached terminal phase of 
the disease. Sacrifice of the i.c.-infected mice in terminal phase started at Day 
143 and ended at Days 177 and 178 in control and CHF5074-treated animals, 
respectively. Sacrifices of the i.p.-infected mice reaching clinical end-point 
took place between Day 192 and Day 221 for the control group, and between 
Day 207 and Day 249 for the treated group. The two CHF5074-treated mice 
showing no abnormal clinical signs were steadily fed with the medicated diet 
until Day 318 and then put on standard diet for 44 additional, days, to verify  if 
the absence of the drug consumption would have allowed the appearance of 
scrapie-related symptoms.  Again, no clinical signs of disease were observed. 
At the end of this period, these two animals were sacrificed. Regarding i.c.-
infected mice, no differences in median survival times were observed between 
CHF5074-treated (161 days) and control (161 days) mice. On the contrary, a 
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significant difference emerged between the median survival times of i.p.-
infected controls (205 days) and CHF5074-treated (226 days) animals (p < 
0.001 Log-Rank test) (Figure 11). 
Figure 11. Survival curve of intraperitoneally infected mice. Log-Rank test indicates a 
significant difference (p < 0.001) between the median survival time of vehicle- and CHF5074-
treated animals (205 versus 226 days, respectively). 
 
11.2.2 - Western blot analysis 
All mice sacrificed at clinical end stage of disease showed presence of PrPSc 
in their brains, characterised by three bands corresponding to di-, mono- and 
un-glycosylated forms with a molecular weight between 30 and 20 kDa. 
Representative Western blot profiles of PrPSc extracted from the brains of i.c.- 
and i.p.-infected mice are shown in Figure 12 and the corresponding 
quantification of densitometric analysis is given in Figure 13. 
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Figure 12. Representative Western blot profiles of PrPSc extracted from the brain of 
intracerebrally (panel A) and intraperitoneally (panel B) infected mice. Lanes A1-A3 show 
three vehicle-treated mice, lanes B1-B4 deal with four CHF5074-treated mice, and lane C- 
considers a control non-infected mouse. PrPSc signals of each sample were quantified 
comparing them with the PrPSc signals of an ovine with classical scrapie (lane C+), used as 
reference. M.w. indicates molecular mass markers. Membrane was probed with monoclonal 
antibody SAF 70. 
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Figure 13. Quantification of PrPSc signals obtained from Western blot analyses of brains of 
intracerebrally (panel A) and intraperitoneally (panel B) infected mice treated with vehicle or 
CHF5074. Columns indicate the mean of optical densities. Error bars represent the standard 
error of the means. 
 
No significant differences appeared between vehicle- and CHF5074-treated 
groups in brain PrPSc levels both in i.c- and i.p.-infected animals. Western blot 
analysis performed on the brains of mice sacrificed without clinical signs of 
disease, including the two i.p.-infected mice treated with CHF5074, did not 
reveal the presence of PrPSc. 
11.2.3 - Histopathological and immunohistochemical 
analysis 
Hematoxylin-eosin staining allowed to detect and score spongiosis in nervous 
tissue and to create a lesion profile of the different encephalic areas. Figure 
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14 illustrates mean spongiosis severity score in different brain areas of the i.c. 
and i.p. infected mice. No significant differences were found between vehicle- 
and CHF5074-treated groups. 
Figure 14. Severity of spongiosis in cerebellum, hippocampus and parietal cortex in 
hematoxilin-eosin stained samples of intracerebrally (panel A) and intraperitoneally (panel B) 
infected mice treated with vehicle or CHF5074. Columns indicate the mean of spongiosis 
severity for each group. Error bars represent the standard error of the means. 
 
 
Immunohistochemical analysis confirmed presence of PrPSc in all the samples 
from symptomatic animals. Representative images of the i.c.- and i.p.-infected 
mice are presented in Figure 15.  
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Figure 15. Representative immunohistochemical staining with monoclonal antibody ICSM 35. 
Panel A: coronal brain sections of intracerebrally infected mice treated with vehicle (A1: 
Cerebellum IHC 20x; A2: Parietal Cortex IHC 20x; A3: Hippocampus IHC 20x); Panel B: 
coronal brain sections of intracerebrally infected mice treated with CHF5074 (B1: Cerebellum 
IHC 20x; B2: Parietal Cortex IHC 20x; B3: Hippocampus IHC 20x); Panel C: coronal brain 
sections of intraperitoneally infected mice treated with vehicle (C1: Cerebellum IHC 20x; C2: 
Parietal Cortex IHC 20x; C3: Hippocampus IHC 20x); Panel D: coronal brain sections of 
intraperitoneally infected mice treated with CHF5074 (D1: Cerebellum IHC 20x; D2: Parietal 
Cortex IHC 20x; D3: Hippocampus IHC 20x). 
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Quantification of PrPSc deposition in i.c. infected mice did not differ between 
vehicle- and CHF5074-treated mice (Figure 16A). Conversely, within i.p. 
infected mice, CHF5074-treated animals showed a significant lower amount of 
PrPSc in their cerebellum (p < 0.05 Student test for unpaired samples), 
hippocampus (p < 0.01 Student test for unpaired samples) and parietal cortex 
(p < 0.05 Student test for unpaired samples) than vehicle-treated animals 
(Figure 16B). 
Figure 16. Mean quantification scores of PrPSc deposition in cerebellum, hippocampus and 
parietal cortex of intracerebrally (A) and intraperitoneally (B) infected mice treated with vehicle 
or CHF5074. Columns indicate mean severity score of PrPSc staining by 
immunohistochemistry (ICSM 35 monoclonal antibodies). Error bars represent the standard 
error of the means. 
 
Histological and immunohistochemical analysis performed on the brains of the 
two i.p. infected animals treated with CHF5074 without neurological signs, 
disclosed the presence neither of PrPSc nor of neuropathological lesions 
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associated to prion diseases. Histopathology and immunohistochemistry 
images of these two animals are reported in Figure 17. 
Figure 17. Histopathological (HE) and immunohistochemical (IHC) images of two 
intraperitoneally-infected mice (Panel A: animal H12; Panel B: animal H13) treated with 
CHF5074 which did not develop neurological signs and survived. 
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11.3 - DISCUSSION 
Chronic oral administration of CHF5074 with the diet (about 60 mg/kg/day) for 
up to 8 months was well tolerated by both scrapie-infected and non-infected 
CD1 mice. Body weight and clinical signs of CHF5074-treated animals were 
similar to those of control mice. Good tolerability of CHF5074 after prolonged 
oral administration has also been observed in previous studies employing 
other mice strains (Imbimbo et al., 2010 a). 
Two intraperitoneally-infected mice treated with a CHF5074-medicated diet 
did not develop any prion disease. We can assume that their inoculations 
failed, even though 2 inefficient inoculations out of 60 are not much likely to 
occur in the same group, i.e. CHF5074-treated, intraperitoneally-infected 
animals, just by chance (p = 0.059, Fisher’s exact test). These animals 
remained asymptomatic even after CHF5074-treatment was over, and 
showed no neuropathological or immunohistochemical abnormalities (Figure 
17). Anyway, in both these cases the median survival time of i.p.-infected 
CHF5074-treated animals remains significantly higher than the median 
survival time of i.p.-infected control mice (i.p. < 0.001 Log Rank test). 
Onset timing and clinical sign pattern observed in other infected animals are 
compatible with those described in mice infected by RML scrapie strain 
(Thackry et al., 2002; Meeker et al., 2005). Histology showed spongiosis, a 
neuropathological feature typical of TSEs, while immunohistochemical and 
Western blot analysis confirmed the presence of PrPSc in the brain of these 
animals without significant regional differences. 
The significant difference related to survival time displayed by CHF5074-
treated and control mice in the i.p. infected group was not observed in the i.c. 
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infected animals. This suggests that CHF5074 concentrations at brain level 
were not high enough to counteract the substantive infection load achieved 
after intracerebral scrapie inoculation. Plasma CHF5074 concentrations 
measured in two i.p.-infected mice were around 270 µM (263 e 282 µM, 
respectively). We did not measure drug brain levels in these animals that, 
based on previous studies, were expected to be about 2-3% of the 
corresponding plasma levels (i.e., 5-8 µM) (Imbimbo et al., 2007; Imbimbo et 
al., 2009). This means that the delayed disease onset due to CHF5074 
treatment should occur during prion propagation from periphery to brain. 
Histological and immunohistochemical analysis of the brains of i.c. infected 
mice did not show significant differences between vehicle- and CHF5074-
treated animals. Conversely, immunohistochemical analysis of i.p. infected 
mice indicated noticeably lower PrPSc deposits in different brain areas 
(cerebellum, hippocampus and parietal cortex) of CHF5074-treated animals 
compared to controls. However, Western blot analysis of a limited brain area 
did not confirm meaningful differences in PrPSc accumulation between 
treatment groups. This apparent discrepancy may be due to the fact that 
immunohistochemistry of paraffin-embedded tissues can highlight PrPSc 
deposits at cellular level and their distribution in different brain areas, whereas 
Western blot assay detects PrPSc at molecular level but can not localize the 
protein as sample preparation requires a homogenization step. Anyway, the 
ability of CHF5074 in reducing PrPSc brain deposits needs to be confirmed in 
further experiments, using antibodies recognising the same PrP residues in 
both immunohistochemistry and Western blot and performing 
immunobiochemical analysis on different brain areas of the same sample. 
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Histological analysis of the brains of i.p. infected mice did not encountered 
significant differences between treatment groups, maybe because spongiosis 
is not directly proportional to PrPSc deposition in the final stages of disease 
(Malucci et al., 2003). 
The protective effect of CHF5074 in this murine model of prion disease must 
be further detected. Prion diseases are characterised by accumulation of 
large amounts of protease-resistant aggregates of an altered isoform (PrPSc) 
of prion protein (PrPC). PrPC normal isoform is a copper binding glycoprotein 
expressed on the surface some cell types, mainly on neurons. Though this 
protein has a relatively short half-life of about an hour, when converted into 
the protease-resistant isoform (PrPSc) it accumulates in the extracellular 
space and can remain there for much longer. Its conversion process is still to 
be thoroughly understood; anyway, it is believed to involve a seeding 
mechanism in which small aggregates are formed over a long period. 
Aggregates that can then rapidly initiate the conversion of more protein, 
resulting in high levels of PrPSc in brain. Accumulation of these aggregates 
there seems to be responsible for the pathology of prion disease (Sakudo et 
al., 2009). Considerable evidence suggests that PrPSc is directly toxic to 
neurons and initiates an apoptotic process that seemingly requires the 
involvement of oxidative stress and microglia activation (Rezaie et al., 2001). 
Studies in transgenic mice models of AD have shown that CHF5074 is able to 
attenuate brain microglia activation associated to Aβ deposits (Imbimbo et al., 
2009; Imbimbo et al., 2010 a). Thus, in scrapie-infected mice CHF5074 may 
counteract PrPSc toxicity mediated by microglia activation. Alternatively, it may 
alter astrocyte migration, a property demonstrated both in vitro (Lichtestein et 
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al., 2010) and in vivo models of AD (Imbimbo et al., 2010 a). Indeed, scrapie-
infected mice show marked reactive astroglyosis around neuropathological 
lesions (Meeker et al., 2005). It has been shown that transgenically 
attenuated astroglyosis in scrapie infected mice led to a reduced 
accumulation of the misfolded isoform of the prion protein PrPSc, a delayed 
disease onset and significantly prolonged survival times (Schultz et al., 2004). 
Therefore, CHF5074-induced beneficial effects in scrapie-infected mice are 
likely to be due to its modulatory effects on reactive astrocytes. 
Alternative processes can also be considered. In prion diseases, cellular 
expression of PrPC is required for neuronal death (Brown et al., 1994; Brown 
et al., 1996), and mice knocked out for the prion protein are resistant to 
infection with prion disease (Büeler et al., 1993; Prusiner et al., 1993). 
Similarly, PrPC is required for impairment of synaptic plasticity induced by Aβ 
oligomers in hippocampal slices (Laurén et al., 2009), and familial AD 
transgenic mice knocked-out for PrPC showed brain Aβ accumulation without 
developing memory deficit (Gimbel et al., 2010). It has been demonstrated 
that CHF5074 attenuated impairment of synaptic plasticity and associated 
memory impairment in young, plaque-free Tg2576 mice without affecting brain 
levels of Aβ oligomers (Balducci et al., 2011). Hypothetically, CHF5074 may 
work in AD transgenic mice by binding and inactivating PrPC on the surface of 
neuronal membrane (Balducci et al., 2011). Similarly, CHF5074 may delay 
prion disease onset acting as antagonist of cell-surface receptors for PrPSc on 
neurons of scrapie-infected mice. 
Therapeutic activity of CHF5074 in the present murine model of prion 
diseases might also be explained considering γ-secretase as the unknown 
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protease involved in the pathologic cleavage of PrPC. A hypothesis that 
seems almost unlikely, however, since γ-secretase exerts its proteolytic 
activity within the plasma membrane, whereas the pathologic breakdown of 
the prion protein is located at the 90-91 N-terminal site (Vincent et al., 2001; 
Evin et al., 2006). The N-terminal portion is an octapeptide repeat region 
binding copper and zinc and usually reputed not to interact with the 
membrane, being PrPC a cell surface glycosyl-phosphatidylinositol (GPI)-
anchored protein. Nevertheless, several in vitro studies indicated that the GPI-
anchor is not obligatory for the raft association of PrP, which can be mediated 
by a determinant within the N-terminal region of the ectodomain (residues 23-
90) (Sanghera et al., 2002; Walmsley et al., 2003; Taylor et al., 2007). 
Furthermore, in vivo studies showed that the N-terminal region strongly 
influenced susceptibility to and incubation times of prion disease (Fischer et 
al., 1996; Moore et al., 2009). The interaction of γ-secretase with the N-
terminal region may then be possible and plausible. An unexpected but not 
isolated event, being the involvement of disintegrin (ADAM) in the 
physiological catabolism of prion protein likewise unusual; substrates of 
disintegrins are indeed generally transmembrane proteins, as APP (Checler et 
al., 2002). 
In conclusion we can state that chronic oral administration of CHF5074 
appears to be a promising treatment not only of AD but also of TSEs, even 
though further studies are definitely needed to confirm its therapeutic potential 
in animal models of prion disease as well as to acquire an in-depth 
understanding of the mechanism underlying its protective effects. 
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12 -  ABILITY TO DETECT BSE AFTER 
CHALLENGE OF WILD TYPE MICE WITH 
BSE AND SCRAPIE MIXTURES 
This experimental study was held at and in collaboration with the Animal 
Health Veterinary Laboratory Agency (AHVLA), Weybridge, Surrey, UK, 
during my internship there (October 1st, 2010 – April 30th, 2011). 
 
The sensitivity of small ruminants to BSE is known (Foster et al., 1993; 
Bellworthy et al., 2008), as well as their exposure to its infectious agent 
through the intake of contaminated MBM (Wilesmith et al., 1991; Smith et al., 
2003). 
Even though an extensive survey of the UK flock has shown no evidence of 
classical BSE phenotype (Stack et al., 2006), its presence can not be 
excluded with certainty (see below). Bellworthy (2008) indeed pointed out that 
the long incubation period of BSE could exceed the commercial lifespan of 
animals, especially if scrapie-affected. 
As in small ruminants scrapie can not be distinguished from BSE on the basis 
of clinical signs (Foster et al., 1993; Baron et al., 2000; Baylis et al., 2002; 
Bellworthy et al., 2008), many experimental studies have been successfully 
aimed to the development of immunoblot and immunohistochemical tests able 
to discriminate between BSE and scrapie (Baron et al., 2000; Jeffrey et al., 
2001; Stack et al., 2002; Jeffrey et al., 2006; Beck et al., 2010 a; Jacobs et al., 
2011). Application of these discriminatory tests in national surveillance 
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projects and retrospective studies to identify BSE in small ruminants revealed 
two caprine BSE cases, one in France (Eloit et al., 2005) and one in UK 
(Spiropoulos et al., 2011). 
Although the discriminatory tests have been validated rigorously on the basis 
that a small ruminant may be affected by either BSE or scrapie, their 
performance on samples where BSE and scrapie prions co-exist has not been 
tested, despite evidence that coinfection of multiple TSE strains in one animal 
is plausible (Bruce et al., 2002; Yokoyama et al., 2010, Mazza et al., 2010). 
Therefore the possibility that sheep and goats in commercial holdings might 
have been affected by BSE which remains undetected due to the 
simultaneous presence of scrapie cannot be excluded unequivocally.  
In contrast to the pathogenesis of BSE in cattle, where the PrPSc distribution is 
limited to the nervous system, except for a short period after oral challenge 
where it can be identified in the Peyer’s patches and in the myenteric plexus 
of the distal ileum (Terry et al., 2003; Hoffman et al., 2007), the peripheral 
pathogenesis of BSE in sheep is similar to that of scrapie with extensive 
distribution of the infectious agent in peripheral tissues (Foster et al., 2001; 
Baylis et al., 2002). 
This widespread distribution of the infectious agent is considered to be the 
main factor responsible for the sheep-to-sheep transmission of scrapie (Baylis 
et al., 2000) and similarly BSE infectivity in a flock could be sustained even 
after the original source of infection is eliminated. Recent evidence seems to 
confirm this hypothesis, suggesting that the sheep BSE propagation within a 
flock is a realistic chance (Bellworth et al., 2005). 
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This possibility ought to be carefully considered, since the peripheral wide 
distribution of BSE prions in sheep suggests that the measures that were 
responsible for the successful eradication of BSE from the cattle population 
would appear inadequate to eliminate BSE in sheep and makes virtually 
impossible to ensure absence of BSE infectivity to consumers after 
consumption of sheep meat products (Baylis et al., 2000). 
It becomes evident that there is a clear need to detect BSE in small ruminants 
not only when it is the only infectious prion but also when it co-exists with 
scrapie. Under such conditions discrimination between BSE and scrapie may 
not be straightforward, as according to the only experimental coinfection study 
where mice were challenged with mixtures of mouse adapted BSE and 
scrapie. The different electrophoretic migration of PrPSc were not enough to 
distinguish the two TSEs strains, because one might mask the other and new 
intermediate banding patterns might be observed (Baron et al., 2001). 
In this second part of my study we investigated the ability of wild-type mouse 
bioassay to identify BSE in the presence of scrapie during primary isolation 
after administration of mixtures of BSE and scrapie using histopathology, 
immunohistochemistry and Western blot. 
12.1 - MATERIALS AND METHODS 
12.1.1 - Ethical statement 
All animal procedures were performed in compliance with the Animal 
(Experimental Procedures) Act 1986 under licence from the UK Home Office, 
and were approved by the local ethics committee.  
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12.1.2 - Inoculum preparation 
Initially a classical scrapie and an ovine BSE homogenate were prepared.  
The classical scrapie inoculum, hereafter referred to as 100% scrapie,  was 
made using a pool of brains collected from natural confirmed cases of 
classical scrapie representing the commonest PrP genotypes, i.e. ARQ/ARQ, 
VRQ/VRQ and ARQ/VRQ. The ovine BSE inoculum, hereafter referred to as 
100% BSE, was prepared from a pool of sheep brains which had been 
challenged experimentally and subsequently succumbed to BSE. The brains 
were homogenised using a handheld blender and suspended in 9 volumes of 
normal saline. Subsequently they were filtered through a single layer of a 
sterile gauze to remove large pieces of tissue, tested for microbiological 
sterility and treated with antibiotics if necessary. Aliquots of these two inocula 
were combined to produce mixtures of BSE and scrapie at the following 
relative ratios: “1 BSE : 99 scrapie” (hereafter referred to as 1% BSE), “2 BSE 
: 98 scrapie” (hereafter referred to as 2% BSE), “10 BSE : 90 scrapie” 
(hereafter referred to as 10% BSE) and “50 BSE : 50 scrapie” (hereafter 
referred to as 50% BSE). All homogenates were stored at -80 oC until they 
were used for inoculations.   
12.1.3 - Animal procedures 
Each inoculum was administered  in three panels of wild type mice namely 
C57Bl6, RIII and VM.  Each panel consisted of 20 mice and each mouse 
received 20 µl of homogenate intracerebrally and 100 µl intraperitonially. 
Inoculations were performed under general anaesthesia using an insulin 
syringe fitted with a 25 gauge needle. Mice were monitored for signs of clinical 
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disease and euthanased either at specified clinical end points or based on 
animal welfare justification After euthanasia each animal was subjected to a 
postmortem examination. The brain was removed and placed in 10% formalin 
and allowed to fix at room temperature for at least three days. 
12.1.4 - Histology 
After fixation was completed the brains were cut at four different coronal 
levels (Figure 18), embedded in wax following standard procedures, 
sectioned, mounted on slides and stained with haematoxylin and eosin for 
histopathological assessment (TSE EU Community Reference Laboratory). 
Figure 18.  Mouse brain. The lines indicate the four neuroanatomical levels where transversal 
cuts are performed (A = frontal level; B = thalamic level; C = mid-brain level; D = medullar 
level). 
 
 
 
 
 
 
 
 
 
 
Based on the existence of convincing TSE specific vacuolation, each sample 
was diagnosed as TSE positive, negative or inconclusive. On TSE positive 
A B C D 
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samples the lesion intensity in specific neuroanatomical areas (Figure 19) was 
further assessed semi-quantitatively and assigned a score on a scale 0-5. The 
lesion scores from clinically and histopathologically positive samples were 
plotted against the respective brain areas to produce lesion profiles as 
described previously (Outram et al., 1973; Green et al., 2005). 
Figure 19. Mouse brain sections and mandatory areas. Areas are made up of grey matter (G 
areas) or white matter (W areas). Medullar section (A): G1 = dorsal medulla nuclei, including 
the cochlear and vestibular nuclei mid-brain level; G2 = cerebral cortex of the folia adjacent to 
the fourth ventricle; W1 = cerebellar white matter. Mid-brain section (B): G3 = dorsal medulla 
nuclei; W2 white matter in the mesencephalic tegmentum. Thalamic section (C): G4 = 
hypothalamus; G5 = central thalamus; G6 = hippocampus; G8 = cerebral cortex; W2 = white 
matter of the pyramidal tract. Frontal section (D): G7 = septal nuclei of the paraterminal body; 
G9 = cerebral cortex. 
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12.1.5 - Western blot 
Western blot analysis were performed on samples from both inocula and wild-
type mice.  
A 5% brain homogenate (200 µl) [in a 0.32 M Sucrose buffer containing 0.5% 
(w/v) DOC (deoxycholic acid sodium salt) and 0.5% (w/v) NP40 (Nonidet-P 
40)] were incubated with 50 µg/ml pK for 60 minutes at 55 °C to completely 
digest all PrPC. The reaction was stopped by addition of 10 mM PMSF 
(phenylmethylsulfonylfluoride). After incubating with 10% sodium N-lauroyl 
sarcosinate and 10mM Tris-HCl, final concentrations (room temperature, 15 
min), proteins were purified by centrifugation (540,000x g, 45 min) over a 10% 
sucrose cushion (250 µl). Pellets were solubilised in Laemmli buffer and 
proteins were separated on 16% Bis/Tris gels, electrotransferred to 
membrane and labelled with specific anti-prion antibody. Immunoreactivity 
was visualised following incubation with chemiluminescence substrate CDP-
Star (Tropix, Bedford, USA). PrPSc in inocula was detected using Sha31 and 
P4 while for mouse brains we used Sha31 and 12B2, as antibody P4 
apparently did not react with murine PrP (data not shown). 
12.1.6 - Immunohistochemical labelling of PrPSc 
Samples from clinically and histopathologically positive mice were further 
analysed with immunohistochemistry as described at 
http://vla.defra.gov.uk/science/docs/sci_tse_rl_prp_ihc.pdf. 
Briefly, PrPSc was detected using RB486, a rabbit polyclonal antibody raised 
against a bovine PrP epitope spanning amino acids 221 to 223, and a 
secondary bioatinylated antibody. Antigen antibodies were developed using a 
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commercial kit (ABC, Vector Laboratories) and diaminobenzidine (DAB) as a 
chromogen. Slides were counterstained in Meyer’s haematoxylin. 
12.1.7 - Statistical analysis 
Cluster analysis was performed using Statistica (Version 10).  For all other 
statistical analyses the STATA (Version 10) or the Genstat (Version 5) 
programmes were used. 
12.2 - RESULTS 
12.2.1 - Attack Rate (AR) and Incubation Period (IP) 
analysis 
The AR expresses the ratio of TSE positive mice over the number of mice 
inoculated with classical scrapie, BSE or their mixtures (n = 20 per group). 
The number of TSE positive mice diagnosed using immunohistochemistry, 
irrespective to their clinical or histopathological status, are presented in Table 
10. All inocula showed high AR in each of the three mouse lines used.  
Significantly, both the 100% scrapie and 100% BSE showed as high attack 
rates as observed with other inocula of the same TSEs in the laboratory of the 
AHVLA of Weybridge, UK, implying that each source represented a high 
infectivity titre. Similarly high attack rates were also recorded for all mixtures. 
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Table 10. Animals positive to immunohistochemistry after classical scrapie and/or BSE 
challange.  
  
Mouse line 
Inoculum RIII C57Bl VM 
100% scrapie 16 15 20 
1% BSE 19 19 19 
2% BSE 16 17 20 
10% BSE 19 18 19 
50% BSE 16 19 20 
100% BSE 16 15 20 
 
The IP data are shown in Figure 20. Generally there is wide overlap between 
all inocula to allow any discrimination even between the controls, 100% 
scrapie and 100% BSE. The only notable observation was the prolonged IP of 
the 100% BSE source in C57Bl mice compared to all other isolates. The 
variance of IP in this group of mice was also increased comparatively to the 
other C57Bl groups. 
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Figure 20. Graphical representation of incubation period data.  Each symbol corresponds to a 
clinically and pathologically TSE positive mouse.  Vertical bars indicate mean values.   
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12.2.2 - Lesion Profile (LP) analysis 
Due to the high infectivity of all inocula there were at least five clinically and 
pathologically positive mice in each mouse group. Therefore it was feasible to 
construct LP from each mouse group (Figure 21). In C57Bl and VM mice the 
LP of 100% BSE was different from that generated by the 100% scrapie 
source. The LP that were generated from the various mixtures seemed to 
align better with the 100% scrapie control rather than the 100% BSE isolate. 
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Figure 21. Lesion profile analysis arising from primary isolation of scrapie, BSE and 
scrapie/BSE mixtures from distinct clusters of wild-type mice. 
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In the RIII mice the LP from mixtures also appear to be more akin to the LP of 
the 100% scrapie source. However in the RIII mice the difference between the 
LP generated by 100% BSE and 100% scrapie sources was not as profound 
as it was in the C57Bl and VM mice. In RIII mice both the 100% BSE and 
100% scrapie produced LP which showed similar contours and the 
differences between them was only quantitative. This property of the RIII has 
been reported extensively elsewhere and the scrapie associated profile has 
been designated 1-4-7 scrapie to denote its similarity with BSE induced LP 
(Beck et al., 2010 a) which consistently produces profiles with peaks in these 
areas (Green et al., 2005). Interestingly this profile has only been derived from 
ARQ/ARQ classical scrapie sources (Beck et al., 2010 a; Beck et al., 2010 b) 
whilst in the current study a pool containing an assortment of the commonest 
ovine PrP genotypes affected by classical scrapie was used.    
12.2.3 - Western blot analysis 
Application of Western blot on the inocula showed that all the mixtures 
essentially behaved as scrapie, showing a higher molecular weight 
unglycosylated band compared to BSE and a binding affinity for antibody P4.  
Application of Western blot on brains of C57Bl and RIII mice also showed that 
animals challenged with mixtures were indistinguishable from those 
challenged with the scrapie control, showing a high molecular weight 
unglycosylated band compared to the BSE control. In addition, affinity to 
antibody 12B2 was retained even in the high mix inocula (10% and 50% 
BSE). No attempt was made to apply Western blot in VM mice as in this 
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mouse line BSE cannot be distinguished from scrapie using this technique 
(Grouschup et al., 2000). 
12.2.4 - Immunohistochemical analysis 
Slides were divided into three groups, according to the three mouse lines 
used: C57Bl, RIII and VM. 
All slides were interpreted by a single assessor. During the first phase the 
100% BSE and 100% scrapie samples were compared unblinded for the 
reader to gain the ability to identify the hallmarks of the PrPSc patterns in mice 
challenged with either pure BSE or scrapie. The remaining slides which 
derived from mice inoculated with 1%, 2%, 10% and 50% BSE were all mixed 
randomly. Subsequently the reader assessed them blind and allocated them 
in their perspective groups based on the PrPSc markers they exhibited. This 
exercise was undertaken to identify potential immunohistochemical markers 
that could be used to identify BSE in a scrapie mixture.   
The BSE infection generated in both C57Bl and RIII mice a mild PrPSc 
deposition, diffuse throughout all the brain in RIII mice and weaker in the 
cranial sections in C57Bl ones. It was characterised by diffuse granular type, 
intraglial and widespread ordered aggregates of various dimensions. This 
pattern was usually denser in locus coeruleus, choclear nuclei, cerebellar 
peduncoli, raphe and red nuclei. In the last ones and in the medulla 
intraneuronal type was also observed. At the thalamic level RIII mice often 
had denser PrPSc deposition in the dorsolateral nuclei of the hypothalamus, 
while C57Bl ones seldom displayed perineuronal type and plaques in the 
zona incerta.  
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The scrapie strain which came out from the pool of inoculum in these two 
mouse lines was the 87A. Unlike BSE, it produced in both C57Bl and RIII 
mice a strong PrPSc deposition in all the brain, made up by intense spread 
granular type, ordered and disordered aggregates, intraglial, some plaques 
and, in defined areas, perineuronal and intraneuronal types too. In the cortex 
of C57Bl mice PrPSc deposition was localised in the molecular and pyramidal 
layers, forming a characteristic double band staining. The scrapie pattern in 
RIII mice usually appeared lateralised in the thalamic level, mainly in the right 
side. 
In both of these mouse lines during BSE and scrapie coinfection the stronger 
scrapie phenotype was dominant on the mild BSE one. Thus no peculiar 
marker able to suggest the presence of BSE in scrapie infected animals has 
been found (Figure 22).  
Figure 22. Comparison of PrPSc deposition patterns in the thalamic level of C57Bl and RIII 
mice following infection with different percentages of BSE and scrapie (100% BSE, 50% BSE 
+ 50% scrapie, 100% scrapie). Scale bars = 500 µm. 
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In VM mice the scrapie strain which emerged from the pool of inoculum was 
the 87V. Both 100% BSE and 100% scrapie infections generated granular 
and intraglial PrPSc pattern. Some intraneuronal deposits were also found in 
medulla and red nuclei. Multifocal small dense aggregates were observed in 
BSE infected animals, while larger ones were occasionally present in thalamic 
and frontal levels. During scrapie infection big dense aggregates were mixed 
with some plaques in all the brain. Rare plaques were occasionally observed 
in the CA1 area of the hippocampus in BSE infected VM mice. Moreover BSE 
induced in this strain of mice very characteristic PsPSc patterns: speckled 
deposition in locus coeruleus, stellate type in hippocampus (Figure 23) and 
diffuse strong punctate pattern. The latter was observed also during scrapie 
87V infection, but was milder, much more localised in few particular areas and 
beads were smaller. 
Figure 23. Unique immunohistochemical patterns are observed in BSE infected VM mice. 
Ovoid dense and spotted deposits, termed “speckled”, frequently appear in locus coeruleus. 
Radiating star-like deposits of PsPSc within the neuropil characterise the BSE pattern in the 
hippocampus. Scale bars = 100 µm. 
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In contrast with speckled and stellate types which were not observed during 
BSE and scrapie coinfection, the BSE-associated punctate pattern appeared 
to be present in some mice that had otherwise a scrapie compatible 
phenotype and so it was chosen as marker of BSE (Figure 24). 
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Figure 24. Representative immunohistochemical staining in neuroanatomical brain areas of 
VM mice infected with different percentages of BSE and scrapie (100% BSE, 50% BSE + 
50% scrapie, 100% scrapie). A: medulla; B: superior colliculus; C: hypothalamus; D: 
thalamus; E: vertical limb of the diagonal band. Scale bars = 50 µm. 
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Subsequently, all samples derived from VM mice challenged with scrapie, 
BSE, or scrapie/BSE mixtures were assorted randomly and assessed blind by 
the same operator. The presence of BSE-associated punctate deposits in 
specific neuroanatomical areas allocated in four coronal levels (medulla, mid-
brain, thalamic and frontal levels) was noted, considering as baseline the 
scrapie-like punctate pattern.  
At each coronal level the number of neuroanatomical areas affected by BSE-
associated punctate deposits was used to predict the presence and 
percentage of BSE (Figure 25). The test predictions were compared to the 
actual values and the associations between test and true status were not 
random (p<0.0001 by Fisher’s exact test). The sensitivity, specificity and 
accuracy of the approach were 78% (62-89), 91% (75-98) and 84% (73-91); 
values in brackets denote 95% confidence intervals. The higher percentage of 
BSE in the mixtures was associated with higher scores of BSE-specific 
punctate deposits and the predictions were more accurate in the high mix 
(50% and 10%) inocula whilst the low mix inocula (2% and 1%) proved more 
difficult to predict accurately. 
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Figure 25. Mean BSE-associated punctate pattern distributions in four coronal brain sections 
of VM mice coinfected with BSE and scrapie. The coronal brain sections reveal: medullar 
level (C1), mid-brain level (C2), thalamic level (C3), frontal level (C4). Animals are grouped on 
the base of the predicted percentage of BSE they received during coinfection.  
 
 
12.3 - DISCUSSION 
Despite the significant progress and development of tests that can 
discriminate BSE from scrapie in a single infection scenario, not enough 
studies that address the performance of the discriminatory tests in cases 
where BSE and scrapie exist in the same animal, sheep or goat, have been 
performed. Ideally, the best possible experimental materials should derive 
from sheep coinfected experimentally with natural scrapie and BSE sources 
via natural routes of inoculation, under conditions that would reflect as close 
as possible naturally occurring coinfection. To the best of our knowledge, 
however, materials from such experiments are not widely available. Therefore 
we used the best possible alternative: we produced BSE and scrapie mixtures 
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in vitro and use them as an alternative to coinfected tissue. A similar approach 
has been followed in the only other study where distinguishing BSE from 
scrapie under coinfection conditions was attempted (Baron et al., 2001). In 
that report the BSE and scrapie sources were mouse adapted sources whilst 
in the current study we used ruminant tissues to replicate closer a scenario 
where potentially coinfected ruminant tissues may be used to challenge 
rodents. Collectively these data suggest that mixtures of scrapie with BSE, 
either of ruminant or mouse adapted sources, behave essentially like scrapie 
as none of the BSE features is retained. 
Based on AR, IP, LP and Western blot our data suggest that all three mouse 
lines that were challenged with BSE/scrapie mixtures exhibited a classical 
scrapie phenotype and it was not possible to identify any BSE attributes in the 
BSE/scrapie mixtures. AR and IP data are considered to be crude parameters 
based on average values derived from a group of animals and as a result they 
cannot always be used to identify with confidence significant differences even 
between different TSE strains. In the current study the BSE derived LP was 
different from that of scrapie particularly in the C57Bl and VM mouse lines. In 
RIII mice, however, LP generated by the BSE and scrapie controls were quite 
similar. Interestingly the LP that was produced by the scrapie control has only 
been generated in the past by ARQ/ARQ classical scrapie sources (Beck et 
al., 2010 a; Beck et al., 2010 b).  
Each mouse that was challenged with either a BSE/scrapie mixture or 100% 
scrapie control in the current study exhibited a stable classical scrapie IHC 
pattern, which is usually isolated from ARQ/ARQ classical scrapie sources 
(Beck et al., 2010 a; Beck et al., 2010 b). In Prnpa mice this IHC pattern was 
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indistinguishable from the one observed in mice challenged with 87A, whilst in 
Prnpb mice it was indistinguishable from the pattern generated by 87V (Beck 
et al., 2010 b). As in classical scrapie a link between ovine PrP genotype and 
strain has been reported (Thackray et al., 2008; Beck et al., 2010 a; Beck et 
al., 2010 b; Thackray et al., 2011), the current finding is intriguing since only 
16% of the scrapie cases that contributed to the 100% scrapie source were 
ARQ/ARQ whilst the majority of the genotypes were either ARQ/VRQ (58%) 
or VRQ/VRQ (20%). A possible explanation could be that a classical scrapie 
strain associated with the ARQ/ARQ genotype was preferentially propagated 
in all three mouse lines at the expense of other strains. This is interesting 
since in our experience it is not unusual to identify individual mice with IHC 
features of different classical scrapie strains on primary passage of single 
isolates or isolate different strains after serial passage particularly when 
ARQ/ARQ cases are bioassayed in C57Bl or RIII mice (Beck et al., 2010 b; 
Thackray et al., 2011). These observations suggest that pooling different 
classical scrapie strains derived from different PrP genotypes in vitro may 
alter their stability or their propagation properties.   
The Western blots from C57Bl and RIII mice that were challenged with 
BSE/scrapie mixtures showed that even with the highest BSE fraction (50%) 
the classical scrapie characteristics dominated and any BSE signal was 
undetectable within the resolution limits of this method.  
Using immunohistochemistry it was not possible to identify any BSE 
characteristics in either C57Bl or RIII mice that were challenged with 
BSE/scrapie mixtures. As with the western blots, these mice were 
indistinguishable from the 100% scrapie control. 
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Collectively the above data indicate that in the C57Bl and RIII mice 
challenged with BSE/scrapie mixtures only classical scrapie phenotypic traits 
were identified. This finding could reflects either a preferential propagation of 
classical scrapie at the expense of BSE in these mouse lines or that although 
BSE was also propagated it had a recessive phenotype. The last suggests 
that propagation of a mixture of two strains is feasible, although in the case of 
C57Bl and RIII mice only one of the two strains may be identifiable.  
Propagation of a mixture of strains is also supported by the data from the VM 
mice where, although the overall phenotype of classical scrapie prevailed, a 
subtle but distinct BSE feature was observed in mice challenged with 
BSE/scrapie mixtures. That feature was more prominent in the mice that were 
exposed to high content of BSE (10% or 50%) compared to those that 
received a low content of BSE (1% or 2%).  
The similarity of results obtained from C57Bl and RIII mice is probably justified 
by the sharing of the same PrP sequence, that influences the TSE-strains 
features, while the PrP sequence in VM mice differs at codons 108 and 109 
(Westway et al., 1987; Bruce et al., 1991). 
Although we were able to identify a BSE-associated trait that could potentially 
be used to detect BSE in the presence of scrapie using VM mice on primary 
isolation, this study shows that overall classical scrapie can dominate the 
phenotype of the disease even if BSE prions propagate in the background.   
It must be noted that the observations of this study cannot be generalised 
without exercising due caution. Firstly the infectious titre of each of the two 
sources that were used to produce the mixtures was not evaluated, therefore 
the mixtures did not reflect a titre ratios but simply the volumetric ratios. 
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In addition, the titres are the function of the strain-host system used (BSE is 
usually titrated in RIII mice whilst scrapie is usually titrated in C57 mice) and 
cross reading between different strain-host systems is not informative. 
Therefore it is questionable if titre matching provides an optimal approach to 
coinfection experiments. However in the current study both sources showed 
very high attack rates, indicating that none of the source inocula had 
unusually low titre. 
Interactions between different classical scrapie strains and BSE is another 
parameter that must be considered. In the current study all mice showed IHC 
patterns that were associated with strains related to the ARQ/ARQ genotype, 
87A in Prnpa mice and 87V in Prnpb mice (Beck et al., 2010 b; Thackray et al., 
2011).  However, it is impossible to predict how other classical scrapie strains, 
such as ME7, would interact with BSE.   
Moreover it must be noted that the selected marker is subtle and only an 
experienced observer could interpret it correctly and only in the high mix BSE 
inocula (10% or 50%), as in the low mix BSE the levels of the marker dropped 
appreciably. Therefore using this model low BSE levels on a classical scrapie 
background may remain undetected. This observation could be extended 
even in the original host (i.e. small ruminants). 
In conclusion, despite all its limits, this is the first study to highlights the 
greater sensitivity of immunohistochemistry compared to histology in detect 
BSE during scrapie/BSE coinfections. It is therefore worth to investigate IHC 
patterns in further mouse lines, in order to find other BSE-markers able to 
improve the accuracy of the diagnosis of coinfection based on the only 
immunohistochemical analysis.  
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Anyway, under these circumstances, a policy of eradicating or minimizing 
classical scrapie is, scientifically and financially, the most feasible option to 
prevent BSE from entering the food chain to a level that could present a public 
health risk. 
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13 - SEARCHING FOR MEMBRANE LIPID ROLE 
IN REGULATORY MECHANISMS OF PRION 
DISEASES: EVALUATION OF DIETARY 
APPROACHES IN MURINE MODEL OF 
SCRAPIE 
Cell membrane consist of a lipid bilayer, mostly unsatured, containing 
phospholipids, cholesterol, sphingolipids, and proteins in dynamic equilibrium. 
The plasma membrane is not homogeneous, but contains specific lipid 
microdomains, mostly saturated, rich in cholesterol and glycosphingolipids, 
like sphingolipids and gangliosides, called lipid rafts (Taylor et al., 2006; Gilch 
et al, 2006; Garattini et al., 2007; Taylor et al, 2007). 
Numerous proteins implicated in cellular homeostasis are located within them 
and it is clear that rafts are important regulators of cellular activity (Garattini, 
2007; Ma et al., 2004). They contain, among the others, ADAM 10 and ADAM 
17 metalloproteases, responsible for the physiological cleavage of PrPC, 
whose activity is regulated modulating the entry of their substrates into the 
lipid rafts. Moreover these domains seem to have a significant role in TSEs, 
being the sites where prion toxic conversion occurs (Gilch et al., 2006; Tellier 
et al., 2006).  
Changes in membrane properties, due to altered lipid composition, affect the 
organization and interact between lipids and protein therein (Ma et al., 2004). 
Alterations in cholesterol and/or ganglioside composition of lipid rafts can 
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significantly affect cell function, being involved in diseases affecting 
neurodegeneration, such as AD and prion diseases (Schengrund et al., 2010). 
Cellular membrane lipids can be remodelled by altering dietary fat intake (Ma 
et al., 2004; Yaqoob, 2009). 
TSEs are characterised by a long incubation period and a difficulty to 
diagnose them in vivo. All the drugs which gave promising therapeutic effects 
demonstrated that, to be effective, had to be administrated preventively or 
close to the infection time and then for long (Trevitt et al., 2006). This 
represent a crucial limit in the therapeutic approach, since means that the 
therapy to be effective would start before knowing to be sick. So prevention 
has a crucial role in counteracting prion diseases. Thus, modulating dietary 
compounds intake seems to be the most reliable and effective way to make 
prevention, rather than encourage preventive medications.  
Starting from these assumptions, the aim of this part of my study is to know if, 
changing in vivo membrane lipid composition using specific diets, it is possible 
to modulate expression, localisation and functionality of certain proteins 
involved in the development of TSEs, and to verify if and how this approach is 
able to influence the clinical progression of prion diseases. Both of the diets 
chosen are expected to have an anti-prionic activity. 
This experimental project has been awarded of the PRIN grant 2009 (Project 
of Relevant National Interest, funded by the Italian Ministry of University and 
Research) and is being performing at the Microbiology and Immunology 
Section of the Department of Veterinary Pathology, Hygiene and Public 
Health, at the School of Veterinary Medicine of the University of Milan. 
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13.1 - DIETS 
13.1.1 - Diet enriched with complex gangliosides 
Gangliosides are a class of sphingolipid conjugated to sugar and N-acetyl 
neuroaminic acid (NANA) molecules, that are present in the outer leaflets of 
all mammalian plasma membranes, where they participate in recognition and 
signalling activity. The five major gangliosides in the brain occurred in the 
order GD1a > GT1b > GD1b > GQ1b > GM1 and together accounted for 70% 
of the total brain gangliosides, while GT1a, GD3 and GM3 contributed to 
approximately 10% of the total. Gangliosides are enriched in lipid rafts in 
neuronal cell membranes and play an important role in brain physiology and 
pathology (Park et al., 2005 a; Yaqoob, 2009; Schengrund et al., 2010). 
Sphingolipid depletion inhibits the intracellular trafficking of GPI-anchored 
proteins, suggesting that lipid-protein interaction directly modulates gene 
expression and cellular trafficking important for cell development and 
behaviour. 
During prion diseases it has been observed a marked decrease in ganglioside 
content, with a shift from complex (GM1, GD1a, GD1b, GT1b, GQ1b) to 
simpler gangliosides (GD3, GM3, GD2) (Naslavsky et al., 1999; Gilch et al., 
2006; Piccinini et al., 2010). GM1 has been often associated with brain 
function and is the ganglioside used most commonly in brain-related research 
(McJarrow et al., 2009) 
Experimental studies demonstrated that animals fed with a ganglioside 
enriched diet (0.02 % of the diet) have significantly higher ganglioside content 
in the intestinal mucosa, plasma and brain, compared with control ones (Park 
et al., 2005 a; McJarrow et al., 2009) and exogenous gangliosides 
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administrated per os seem to be directly incorporated into the microdomains 
(Park et al., 2005 b). 
Moreover, an oral integration of gangliosides results in a significant lowering 
of microdomain cholesterol levels (see below) (Park et al., 2005 b). 
13.1.2 - Low cholesterol diet 
The brain consist of ~ 2% cholesterol that comes from primarily de novo 
synthesis. Astrocytes provide cholesterol needed by the CNS and 
apolipoprotein E (apoE). Cholesterol and apoE are released as a complex 
that is taken up by neurons via receptor-mediated endocytosis. Cholesterol is 
essential for normal neuronal development and it appears to play important 
roles in regulating synaptic plasticity, memory encoding and storage (Pfrieger, 
2003; Schengrund et al., 2010). 
Research demonstrated that cholesterol content of the brain increased during 
scrapie infection, raising the possibility that the presence of PrPSc alters the 
composition and function of lipid rafts, the integrity of which is necessary for 
synaptic functions (Kempster et al., 2007). Drugs able to inhibit the synthesis 
of cholesterol (statins) have proved to have an anti-prionic activity (Bate et al., 
2004). 
Statins act as reversible competitive inhibitors of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG–CoA) reductase, which, as the key rate-controlling 
enzyme in cholesterol biosynthesis, catalyses the conversion of HMG–CoA to 
mevalonic acid. Statins are categorized pharmacologically as lipophilic (i.e. 
lovastatin and simvastatin) or hydrophilic (i.e. pravastatin) compounds, 
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depending on their solubility in lipid solvents or water; both of them are able to 
cross the blood brain barrier (Vetrugno et al., 2009). 
Statins are known to reduce the formation of  the disease-associated isoform 
of the prion protein (PrPSc) in neuroblastoma cells in vitro (Bate et al., 2004). 
In murine prion models, statins administration (both at high- and low-dosage, 
the last usually used to treat hypercholesterolemia in humans) affect the 
progression of experimental scrapie, delaying disease progression and 
prolonging survival times (Mok et al., 2006; Kempster et al., 2007; Vetrugno et 
al., 2009).  
The lower formation of PrPSc after cholesterol depletion induced by statins is 
related to the reduced expression of PrPC on the cell membranes, which is 
presumably due to the disruption of the lipid rafts structure and/or to the 
prevention of the plasma membrane surface transport of the cellular prion 
protein. Cholesterol indeed is essential both in lipid rafts stability and in the 
secretory pathway of PrPC (Taraboulos et al., 1995; Gilch et al., 2006). 
Furthermore, cholesterol and gangliosides content in lipid rafts is tightly 
related and a depletion of cholesterol was shown to enhance expression of 
GM1, ganglioside with neuroprotective properties (Park et al., 2005 a; 
Schengrund et al., 2010). 
13.2 - EXPERIMENTAL PROJECT 
For this research project we are going to use the CD1 mouse model. Animals 
have been challenged via intraperitoneal route (i.p.) with the scrapie strain 
adapted to mice Rocky Mountain Laboratory (RML) and fed with medicated 
feed (low cholesterol diet or diet enriched with complex gangliosides) since 
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two weeks before mice inoculation. Four control groups have been formed: 
the “positive” control one, scrapie-infected and fed with standard feed, and 
three “negative” control groups, made up of animals challenged with a mouse 
brain homogenate from an healthy TSE-free animal and fed with the low 
cholesterol diet, with ganglioside-enriched diet or with the standard feed, 
respectively. Each of these six groups will consist of 15 elements (Table 11).  
Table 11. Mice have been randomly divided into groups depending on the type of diet and 
scrapie challenged. 
 
Feed consumption and animal weights are recorded weekly. Mice are 
carefully monitored to detect the onset and the progression of scrapie-induced 
symptoms and will be euthanized using CO2 at the terminal stage of disease. 
Animal survival times will be noted and, after necroscopy, their brains will be 
investigated by histological, immunohistochemical and Western blot analysis. 
The content of cholesterol and GM1 in lipid domains of the cortex and 
cerebellum and the localization of ADAM 10, ADAM 17 and prion protein will 
Group Scrapie challenged Diet
A yes standard 15
B yes low cholesterol 15
C yes ganglioside-enriched 15
D no standard 15
E no low cholesterol 15
F no ganglioside-enriched 15
Number of 
animals
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be analysed at the Department of Neuropathology at the University of  
Bicocca in Milan. 
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14 - ABBREVIATIONS 
AD: Alzheimer’s Disease 
ADAM: A disintegrin and metalloprotease 
AHVLA: Animal Health Veterinary Laboratory Agency 
APH-1: Anterior Pharinx 1 
APP: Amylois precursor protein 
AR: Attack rate 
ARR: A136R154R171 
Aβ: Amyloid-β 
BAB: Born after ban 
BACE: β-site APP-cleaving-enzyme 
BSE: Bovine Spongiform Encephalopathy 
CHF5074: 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-
cyclopropanecarboxylic Acid 
CJD: Creutzfeldt-Jakob Disease 
CNS: Central nervous system 
CR: Congo Red 
CWD: Chronic Wasting Disease 
DAB: Diaminobenzidine 
DMNV: Dorsal motor nucleus of the vagus 
DOC: deoxycholic acid sodium salt 
ENS: Enteric nervous system 
FAE: Follicle associated epithelium 
FDC: Follicular dendritic cell 
GAGs: Glycosaminoglycans 
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GALT: Gut-associated lymphoid tissues 
GPI: glycosylphosphatidylinositol 
GSS: Gerstman-Straussler-Scheinker 
HE: Histopathological 
i.c.: Intracerebral 
i.p.: Intraperitoneal 
IHC: immunohistochemical 
IMLC: Intermediolateral column 
IP: incubation period 
LF: Lymphoid follicles 
LP: lesion profile 
LRS: Lymphoreticular system 
m.w.: Molecular weight 
MBM: Meat and bone meal 
M-cells: membranous epithelial cells 
Met: Methionine 
NP40: Nonidet-P 40 
PAGE: polyacrylamide gel electrophoresis 
PEN-2: Presenilin enhancer 2 
PGs: Proteoglycans 
pK: Proteinase K 
PKC: Protein kinase C 
PMCA: Protein misfolding cyclic amplification 
PMSF: phenylmethyl sulfonyl fluoride 
PNS: peripheral nervous system 
  
 
133
PrPC: cellular prion protein 
PrPSc: Prion 
PrPSen: Protease-sensitive prion protein 
PS: Presenilin 
RNAi: Ribonucleic acid interference 
SAF: Scrapie associated fibril 
sAPPα: Secreted APP 
SDS: Sodium dodecyl sulfate 
TACE: Tumor necrosis factor α converting enzyme 
TME: Transmissible Mink Encephalopathy 
TSE: Transmissible Spongiform Encephalopathy  
vCJD: variant Creutzfeldt-Jakob Disease 
WB: Western blot 
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